{"ID": "1888B8EBC038469D4B8478C79FEB8284", "URL": "https://www.ema.europa.eu/documents/product-information/neofordex-epar-product-information_en.pdf", "Product_Name": "Neofordex", "Full_Content": "1 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nANNEX I \n \n\nSUMMARY OF PRODUCT CHARACTERISTICS \n\n\n\n2 \n\n1. NAME OF THE MEDICINAL PRODUCT \n \nNeofordex 40 mg tablets \n \n \n2. QUALITATIVE AND QUANTITATIVE COMPOSITION \n \nEach tablet contains dexamethasone acetate equivalent to 40 mg dexamethasone. \n \nExcipient with known effect \n \nEach tablet contains 98.1 mg lactose. \nFor the full list of excipients, see section 6.1. \n \n \n3. PHARMACEUTICAL FORM \n \nTablet \nWhite, oblong (11 mm \u00d7 5.5 mm) tablet with a score-line on one face. \nThe tablet can be divided for administration of a 20 mg dose (see section 4.2). \n \n \n4. CLINICAL PARTICULARS \n \n4.1 Therapeutic indications \n \nNeofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with \nother medicinal products. \n \n4.2 Posology and method of administration \n \nTreatment must be initiated and monitored under the supervision of physicians experienced in the \nmanagement of multiple myeloma. \n \nPosology \n \nThe dose and administration frequency varies with the therapeutic protocol and the associated treatment(s). \nNeofordex administration should follow instructions for dexamethasone administration when described in \nthe Summary of Product Characteristics of the associated treatment(s). If this is not the case, local or \ninternational treatment protocols and guidelines should be followed. Prescribing physicians should carefully \nevaluate which dose of dexamethasone to use, taking into account the condition and disease status of the \npatient. \n \nThe usual posology of dexamethasone is 40 mg once per day of administration. \n \nAt the end of dexamethasone treatment, the dose should be tapered in a stepwise fashion until a complete \nstop. \n \nMissed dose \nThe tablet should be taken immediately if the dose was missed for less than 12 hours. \nThe next tablet should be taken at the usual time, if the dose was missed for more than 12 hours. \nIn case of a missed dose, a double dose must not be taken. \n \nSpecial population \n \nElderly  \n\n\n\n3 \n\nIn elderly and/or frail patients, the daily dose may be reduced to 20 mg of dexamethasone, according to the \nappropriate treatment regimen. \n \nHepatic impairment  \nPatients with hepatic impairment require appropriate monitoring and should be dosed with caution as there \nare no data for this patient population (see sections 4.4 and 5.2). \n \nRenal impairment \nPatients with renal impairment require appropriate monitoring (see section4.4). \n \nPaediatric population \nThere is no relevant use of Neofordex in the paediatric population for the indication of multiple myeloma. \n \nMethod of administration  \n \nOral use.  \n \nIn order to minimise insomnia, the tablet should preferably be taken in the morning. \n \nTablets should be kept in the blister package until administration. Individual tablets in intact packaging \nshould be separated from the blister using the perforation, e.g. for use in multi-compartment compliance aids. \n \nTablets may be broken in two equal halves using the score line to provide the 20mg dose. Due to possible \nstability issues affecting half tablets stored after division, half-tablets that are not taken immediately \nshould be discarded in agreement with local precautions for environmental protection (see also 6.4).  \n \n4.3 Contraindications \n \nHypersensitivity to the active substance or to any of the excipients listed in section 6.1. \n \nActive viral disease (especially viral hepatitis, herpes, varicella, shingles). \n \nUncontrolled psychoses. \n \nWhen dexamethasone is given in combination with other medicinal products, refer to their Summaries of \nProduct Characteristics for additional contraindications. \n \n4.4 Special warnings and precautions for use \n \nDexamethasone is a high-dose glucocorticoid. This should be taken into consideration in the surveillance of \nthe patient. The benefit from dexamethasone treatment should be carefully and continuously weighed against \nactual and potential risks. \n \nRisk of infection \n \nTreatment with high-dose dexamethasone increases the risk of developing serious infections, in particular \ndue to bacteria, yeasts and/or parasites. Such infections can also be caused by microorganisms that rarely \ncause disease under normal circumstances (opportunistic infections). Signs of a developing infection may be \nmasked by dexamethasone therapy.  \n \nBefore the start of treatment, any source of infection, especially tuberculosis, should be removed. During \ntreatment, patients should be closely monitored for the appearance of infections. In particular, pneumonia \noccurs commonly. Patients should be informed of the signs and symptoms of pneumonia and be advised to \nseek medical attention in case of their appearance. In case of active infectious disease, appropriate \nanti-infective treatment must be added to the treatment with dexamethasone. \n \n\n\n\n4 \n\nIn cases of prior tuberculosis with major radiological sequelae or if it is not certain that a full 6-month \nrifampicin treatment course has been followed, a prophylactic anti-tuberculosis treatment is required. \n \nThere is a risk of severe strongyloidiasis. Patients from endemic areas (tropical and sub-tropical regions, \nsouthern Europe) should have a stool examination and if required an eradication of the parasite before \ninitiating dexamethasone treatment. \n \nCertain viral diseases (varicella, measles) can be aggravated in patients receiving glucocorticoid treatment or \nwho have received glucocorticoid treatment within the previous 3 months. Patients must avoid contact with \nsubjects with chickenpox or measles. Immunocompromised patients who have not previously had \nchickenpox or measles are particularly at risk. If such patients have been in contact with people with \nchickenpox or measles, a preventive treatment with intravenous normal immunoglobulin or passive \nimmunisation with varicella zoster immunoglobulin (VZIG) must be started as appropriate. Exposed patients \nshould be advised to seek medical attention without delay. \n \nVaccinations \n \nDexamethasone should not be used with live attenuated vaccines (see section 4.5). Vaccinations with \ninactivated vaccines are usually possible. However, the immune response and hence the effect of the \nvaccination can be diminished by high glucocorticoid doses. \n \nInterference with laboratory tests \n \nDexamethasone can suppress skin reaction to allergy testing. It can also affect the nitro blue tetrazolium \n(NBT) test for bacterial infections and cause false-negative results.   \n \nPsychiatric disorders \n \nPatients and/or carers should be warned that potentially severe psychiatric adverse reactions may occur with \nsystemic steroids (see section 4.8). Symptoms typically emerge within a few days or weeks of starting the \ntreatment. Risks may be higher with high doses (see also section 4.5 for pharmacokinetic interactions that \ncan increase the risk of adverse reactions), although dose levels do not allow prediction of the onset, type \nseverity or duration of reactions. Most reactions recover after either dose reduction or withdrawal, although \nspecific treatment may be necessary. Patients/carers should be encouraged to seek medical advice if \nworrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected. \nPatients/carers should also be alert to possible psychiatric disturbances that may occur either during, or \nimmediately after, dose tapering/withdrawal of systemic steroids, although such reactions have been reported \ninfrequently.  \n \nParticular care is required when considering the use of systemic corticosteroids in patients with existing or \nprevious history of severe affective disorders in themselves or in their first degree relatives. These would \ninclude depressive or manic-depressive illness and previous steroid psychoses.  \n \nInsomnia may be minimised by administering Neofordex in the morning. \n \nTumour lysis syndrome \n \nIn post marketing experience tumour lysis syndrome (TLS) has been reported in patients with \nhaematological malignancies following the use of dexamethasone alone or in combination with other \nchemotherapeutic agents. Patient at high risk of TLS, such as patients with high proliferative rate, high \ntumour burden, and high sensitivity to cytotoxic agents, should be monitored closely and appropriate \nprecaution taken. \n \nGastrointestinal disorders \n \nTreatment for active gastric or duodenal ulceration should be commenced prior to initiation of \ncorticosteroids. Appropriate prophylaxis should be considered for patients with a previous history of, or risk \n\n\n\n5 \n\nfactors for, gastric or duodenal ulceration, haemorrhage or perforation. Patients should be monitored \nclinically, including by endoscopy. \n \nEye disorders \n \nSystemic treatment with glucocorticoids can induce chorioretinopathy which may result in impaired vision \nincluding loss of vision. \n \nProlonged use of corticosteroids may produce subcapsular cataracts, glaucoma with possible damage to the \noptic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. \nParticular care is needed when treating patients with glaucoma (or family history of glaucoma) as well as \nwhen treating patients with ocular herpes simplex, because of possible corneal perforation. \n \nTendonitis  \n \nCorticosteroids can favour the development of tendonitis and, in exceptional cases, rupture of the affected \ntendon. This risk is increased by concomitant use of fluoroquinolones and in patients undergoing dialysis \nwith secondary hyperparathyroidism or after renal transplantation. \n \nPheochromocytoma crisis  \n \nPheochromocytoma crisis, which can be fatal, has been reported after administration of systemic \ncorticosteroids. Corticosteroids should only be administered to patients with suspected or identified \npheochromocytoma after an appropriate risk/benefit evaluation. \n \nElderly \n \nThe common adverse reactions to systemic corticosteroids may be associated with more serious \nconsequences in old age, especially osteoporosis, hypertension, hypokalaemia, diabetes, susceptibility to \ninfection and thinning of the skin. Close clinical supervision is required to avoid life-threatening reactions. \n \nMonitoring \n \nUse of corticosteroids requires appropriate monitoring in patients with ulcerative colitis (due to perforation \nrisk), recent intestinal anastomoses, diverticulitis, recent myocardial infarction (risk of left ventricular free \nwall rupture), diabetes mellitus (or family history), renal insufficiency, hepatic impairment, osteoporosis and \nmyasthenia gravis. \n \nLong-term treatment \n \nDuring treatment, a diet low in simple sugars and high in protein should be followed due to the \nhyperglycaemic effect of corticosteroids and their stimulation of protein catabolism with a negative nitrogen \nbalance. \n \nWater and sodium retention is common and can lead to hypertension. Sodium intake should be reduced and \nblood pressure should be monitored. Particular care is needed when treating patients with renal impairment, \nhypertension or congestive heart failure. \n \nPotassium levels should be monitored during treatment. Potassium supplementation should be given \nparticularly if there is a risk of cardiac arrhythmia or concurrent hypokalaemic medicinal products. \n \nGlucocorticoid therapy may reduce the effect of anti-diabetic and antihypertensive treatment. The dose of \ninsulin, oral anti-diabetics and anti-hypertensive medicinal products may have to be increased. \n \nDepending on the duration of treatment, calcium metabolism may be impaired. Calcium and vitamin D levels \nshould be monitored. In patients not already prescribed bisphosphonates for multiple myeloma related bone \ndisease, bisphosphonates should be considered, particularly if risk factors for osteoporosis are present. \n\n\n\n6 \n\n \n \nUse in combination with other multiple myeloma treatment(s) \n \nWhen Neofordex is given in combination with other medicinal products, the Summary of Product \nCharacteristics of these other medicinal products must be consulted prior to initiation of treatment \nwith Neofordex.  \n \nWhen Neofordex is used in combination with known teratogens (e.g. thalidomide, lenalidomide, \npomalidomide, plerixafor), particular attention to pregnancy testing and prevention requirements is \nneeded (see section 4.6). \n \nVenous and arterial thromboembolic events \nIn patients with multiple myeloma, the combination of dexamethasone with thalidomide and its analogues is \nassociated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and \npulmonary embolism) and arterial thromboembolism (predominantly myocardial infarction and \ncerebrovascular event) (see sections 4.5 and 4.8). \n \nConsequently, patients with known risk factors for thromboembolism (including prior thrombosis) should be \nclosely monitored. Action should be taken to try to minimise all modifiable risk factors (e.g. smoking, \nhypertension, and hyperlipidaemia). Concomitant administration of erythropoietic medicinal products may \nalso increase thrombotic risk in these patients. Therefore, erythropoietic medicinal products, or other \nmedicinal products that may increase the risk of thrombosis, such as hormone replacement therapy, should \nbe used with caution in multiple myeloma patients receiving dexamethasone with thalidomide and its \nanalogues. A haemoglobin concentration above 12 g/dl should lead to discontinuation of erythropoietic \nmedicinal products. \n \nPatients and physicians are advised to be observant for the signs and symptoms of thromboembolism. \nPatients should be instructed to seek medical care if they develop symptoms such as shortness of breath, \nchest pain, arm or leg swelling. Prophylactic antithrombotic treatment should be recommended, especially in \npatients with additional thrombotic risk factors. The decision to take antithrombotic prophylactic measures \nshould be made after careful assessment of an individual patient\u2019s underlying risk factors. \n \nIf the patient experiences any thromboembolic events, treatment must be discontinued and standard \nanticoagulation therapy started. Once the patient has been stabilised on the anticoagulation treatment and any \ncomplications of the thromboembolic event have been managed, the treatment with dexamethasone and \nthalidomide or its analogues may be restarted at the original dose dependent upon a benefit risk assessment. \nThe patient should continue anticoagulation therapy during the course of treatment with dexamethasone and \nthalidomide or its analogues.  \n \nNeutropenia and thrombocytopenia \nThe combination of dexamethasone with lenalidomide in multiple myeloma patients is associated with a \nhigher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared \nwith 0.6% in placebo/dexamethasone-treated patients; see section 4.8). Grade 4 febrile neutropenia episodes \nwere observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to 0.0% in \nplacebo/dexamethasone treated patients; see section 4.8). Neutropenia was the most frequently reported \nGrade 3 or 4 haematological adverse reaction in patients with relapsed/refractory multiple myeloma treated \nwith the combination of dexamethasone with pomalidomide. Patients should be monitored for \nhaematological adverse reactions, especially neutropenia. Patients should be advised to promptly report \nfebrile episodes. A dose reduction of lenalidomide or pomalidomide may be required. In case of neutropenia, \nthe physician should consider the use of growth factors in patient management. \n \nThe combination of dexamethasone with lenalidomide in multiple myeloma patients is associated with a \nhigher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in \nlenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated \npatients) (see section 4.8). Thrombocytopenia was also reported very commonly by patients with \n\n\n\n7 \n\nrelapsed/refractory multiple myeloma treated with the combination of dexamethasone with pomalidomide. \nPatients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae \nand epistaxes, especially in case of concomitant treatment susceptible to induce bleeding. A dose reduction \nof lenalidomide or pomalidomide may be required. \n \nA complete blood cell count, including white blood cell count with differential count, platelet count, \nhaemoglobin, and haematocrit should be performed at baseline, every week for the first 8 weeks of \ndexamethasone/lenalidomide treatment and monthly thereafter to monitor for cytopenias. \n \nLactose intolerance \n \nNeofordex contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase \ndeficiency or glucose-galactose malabsorption should not take this medicinal product. \n \n4.5 Interaction with other medicinal products and other forms of interaction \n \nPrior to the use of Neofordex in combination with any other medicinal product, reference should be \nmade to the Summary of Product Characteristics of that product. \n \nPharmacodynamic interactions \n \nThe following combinations should be avoided due to safety concerns \n\u2022 With acetylsalicylic acid, at doses \u2265 1 g per dose or 3 g per day, due to an increased risk of bleeding. \n\nAt doses \u2265 500 mg per dose or < 3 g per day, precautions are required due to increased risk of \nhaemorrhage, ulcerations and gastro-intestinal perforation. However, antithrombotic prophylaxis with \nlow-dose acetylsalicylic acid is possible;  \n\n\u2022 With live attenuated vaccines, due to risk of vaccine-related illness with risk of death (see section 4.4). \n \nThe following combinations require precautions due to safety concerns \n\u2022 With hypokalaemic medicinal products: hypokalemic diuretics, single or in combination, laxatives, \n\ntetracosactide, intravenous amphotericin B, due to increased risk of hypokalaemia. Potassium levels \nshould be monitored and corrected as necessary. In addition, amphotericin B carries a risk of cardiac \nenlargement and cardiac failure with concurrent use. \n\n\u2022 With digitalis, as hypokalaemia enhances the toxic effects of digitalis. Any hypokalaemia should be \ncorrected and patients should be monitored clinically, for electrolytes and by electrocardiograpy. \n\n\u2022 With medicinal products that carry a risk of Torsades de Pointes, due to increased risk of ventricular \narrhythmia. Any hypokalaemia should be corrected and patients should be monitored clinically, for \nelectrolytes and by electrocardiography. \n\n\u2022 With erythropoietic medicinal products or other medicinal products that may increase the risk of \nthrombosis, such as hormone replacement therapy, in patients receiving thalidomide or its analogues \nwith Neofordex (see sections 4.4 and 4.8). \n\n\u2022 With non-steroidal anti-inflammatory drugs (NSAIDs), due to an increased risk of gastrointestinal \nulceration. \n\n\u2022 With hypoglycaemic medicinal products, as dexamethasone can raise glycaemic levels and diminish \nglucose tolerance, with a possibility of ketoacidosis. Patients should be made aware of this risk and \nself-monitoring of blood and urine should be reinforced, especially during the initiation of treatment. \nThe posology of anti-diabetic medicinal products may have to be adjusted during and after the \ntreatment with dexamethasone. \n\n\u2022 With anti-hypertensive medicinal products, due to a reduction of their effect (water and sodium \nretention). The dose of the anti-hypertensive treatment may have to be adjusted during the treatment \nwith dexamethasone. \n\n\u2022 With fluoroquinolones, due to possibly increased risk of tendonitis and, in exceptional cases, rupture \nof the affected tendon, particularly after long-term treatment. \n\n\u2022 With methotrexate, due to an increased risk of haematological toxicity. \n \n\n\n\n8 \n\nPharmacokinetic interactions \n \nEffects of other medicinal products on dexamethasone \nDexamethasone is metabolized via cytochrome P450 3A4 (CYP3A4), and transported by the P-glycoprotein \n(P-gp, also known as MDR1). Concomitant administration of dexamethasone with inducers or inhibitors of \nCYP3A4 or P-gp may lead to decreased or increased plasma concentrations of dexamethasone, respectively. \n \nThe following combinations require precautions due to changes in dexamethasone pharmacokinetics \n \n\u2212 Medicinal products that may reduce dexamethasone plasma concentration: \n\u2022 Aminogluthetimide, due to a reduction of the efficacy of dexamethasone through an increase of its \n\nhepatic metabolism.  \n\u2022 Anticonvulsants that are hepatic enzyme inducers: carbamazepine, fosphenytoin, phenobarbital, \n\nphenytoin, primidone, due to the reduction of dexamethasone plasma levels and hence its efficacy.  \n\u2022 With rifampicin, due to reduction of dexamethasone plasma concentrations and efficacy by an increase \n\nof its hepatic metabolism.  \n\u2022 Topical gastro-intestinal medicinal products, antacids and activated carbon, as well as colestyramine, \n\ndue to reduction of the intestinal absorption of dexamethasone. The administration of such medicinal \nproducts and Neofordex should be separated by at least two hours. \n\n\u2022 Ephedrine, due to a reduction in dexamethasone plasma levels by increased metabolic clearance. \n\u2212 Medicinal products that may increase dexamethasone plasma concentration: \n\u2022 Aprepitant and fosaprepitant, due to an increase of dexamethasone plasma concentrations by a \n\nreduction of its hepatic metabolism.  \n\u2022 Clarithromycin, erythromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, \n\nnelfinavir, ritonavir: Increased dexamethasone plasma concentration due to reduction of its hepatic \nmetabolism by these enzyme inhibitors. \n\n \nEffects of dexamethasone on other medicinal products \nDexamethasone is a moderate inducer of CYP3A4 and of P-gp. Concomitant administration of \ndexamethasone with substances that are metabolised via CYP3A4 or transported by P-gp could lead to \nincreased clearance and decreased plasma concentrations of these substances:  \n \n\u2022 Oral contraceptives, as it cannot be excluded that the efficacy of oral contraceptives may be reduced \n\nduring treatment. No interaction study has been performed with oral contraceptives. Effective \nmeasures to avoid pregnancy must be taken (see section 4.6). Efficacy of hormone replacement \ntherapy may also be reduced. \n\n\u2022 Oral anticoagulants, due to a possible impact of corticosteroids on the metabolism of the oral \nanticoagulant and on coagulation factors, as well as the haemorrhagic risk (mucosa of the digestive \ntract, vascular fragility) of dexamethasone therapy itself at high doses or treatment periods above \n10 days. It the combination is required, monitoring should be reinforced and coagulation parameters \ncontrolled after one week and then every other week of treatment as well as after the end of treatment. \n\n\u2022 Docetaxel and cyclophosphamide, due to reduction of their plasma levels by induction of CYP3A and \nP-gp.  \n\n\u2022 Lapatinib, due to increased hepatotoxicity of lapatinib likely due to induction of CYP3A4 metabolism. \n\u2022 Ciclosporin, due to a reduction of ciclosporin bioavailability and plasma levels. Ciclosporin may also \n\nincrease the intracellular uptake of dexamethasone. In addition, convulsions have been reported with \nconcurrent use of dexamethasone and ciclosporin. Concomitant use of dexamethasone and \nciclosporine should be avoided. \n\n\u2022 Midazolam, due a reduction in midazolam plasma levels by CYP3A4 induction. The efficacy of \nmidazolam may be reduced. \n\n\u2022 Ivermectin, due to a reduction of ivermectin plasma levels. Parasite eradication must be successfully \nterminated before dexamethasone use (see section 4.4). \n\n\u2022 Rifabutin, due to reduced rifabutin plasma levels by induction of intestinal and hepatic CYP3A4.  \n\u2022 Indinavir, due to a strong reduction of indinavir plasma levels by intestinal CYP3A4 induction. \n\u2022 Erythromycin, due to increased metabolism of erythromycin in non-carriers of the CYP3A5*1 allele \n\nafter dexamethasone treatment. \n\n\n\n9 \n\n\u2022 Isoniazid, as glucocorticoids may decrease isoniazid plasma concentrations, probably due to a \nstimulation of hepatic metabolism of isoniazid and a reduction of glucocorticoid metabolism. \n\n\u2022 Praziquantel, due to the reduction of praziquantel plasma concentrations due to an increase of its \nhepatic metabolism by dexamethasone, with a risk of failure of treatment. The treatments with the two \nmedicinal products should be separated by at least one week. \n\n \nRepeated, daily administration of dexamethasone also leads to reduced dexamethasone plasma levels due to \nthe induction of CYP3A4 and P-gp. No dose adjustment is needed in the treatment of multiple myeloma. \n \nDexamethasone has no clinically significant pharmacokinetic interaction with thalidomide, lenalidomide, \npomalidomide, bortezomib, vincristine or doxorubicin. \n \n4.6 Fertility, pregnancy and lactation \n \nWomen of childbearing potential \n \nWomen should avoid pregnancy during Neofordex treatment. Dexamethasone may cause congenital \nmalformations (see section 5.3). Dexamethasone may be used with known teratogens (e.g. thalidomide, \nlenalidomide, pomalidomide, plerixafor), or with cytotoxic substances which are contraindicated in \npregnancy. Patients receiving Neofordex in combination with products containing thalidomide, lenalidomide \nor pomalidomide should adhere to the pregnancy prevention programmes of those products. Reference \nshould be made to all the relevant Summary of Product Characteristics prior to the commencement of any \ncombination treatment for additional information.  \n \nContraception in males and females \n \nWomen of childbearing potential and their male partners should take appropriate contraceptive measures. In \nparticular, the requirements of the pregnancy prevention programme for combination treatment with \nthalidomide or its analogues must be followed. The efficacy of oral contraceptives may be reduced during \ndexamethasone treatment (see section 4.5). \n \nPregnancy \n \nBased on human experience, dexamethasone is suggested to cause congenital malformations, particularly \nintra-uterine growth retardation and rarely neonatal adrenal insufficiency, when administered during \npregnancy.  \nStudies in animals have shown reproductive toxicity (see section 5.3). \n \nNeofordex should not be used during pregnancy unless the clinical condition of the woman requires \ntreatment with dexamethasone. \n \nBreast-feeding \n \nGlucocorticoids are excreted in human milk and effects have been shown in breastfed newborns/infants of \ntreated women. \nA decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Neofordex \ntherapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the \nwoman. \n \nFertility \n \nStudies in animals have shown reductions in female fertility (see Section 5.3). No data on male fertility are \navailable. \n \n4.7 Effects on ability to drive and use machines \n \n\n\n\n10 \n\nNeofordex has moderate influence on the ability to drive and use machines. \nDexamethasone may cause confusional state, hallucinations, dizziness, somnolence, fatigue, syncope and \nblurred vision (see section 4.8). If affected, patients should be instructed not to drive, use machines or \nperform hazardous tasks while being treated with dexamethasone.  \n \n4.8 Undesirable effects \n \nSummary of the safety profile  \n \nAdverse reactions to Neofordex correspond to the predictable safety profile of glucocorticoids. \nHyperglycaemia, insomnia, muscle pain and weakness, asthenia, fatigue, oedema and weight increase occur \nvery commonly. Less common but serious adverse reactions include: pneumonia and other infections and \npsychiatric disorders (see section 4.4). In combination with thalidomide or its analogues the most serious \nadverse reactions were venous thromboembolic events, predominantly deep vein thrombosis and pulmonary \nembolism, and myelosuppression, particularly neutropenia and thrombocytopenia (see section 4.4). \n \nThe incidence of predictable adverse reactions, including adrenal atrophy, correlates with dose, timing of \nadministration and the duration of treatment (see section 4.4). \n \nTabulated list of adverse reactions \n \nThe adverse reactions observed in patients treated with dexamethasone are listed below by system organ \nclass and frequency. Frequencies are defined as: very common (\u2265 1/10); common (\u2265 1/100 to < 1/10); \nuncommon (\u2265 1/1,000 to < 1/100); rare (\u2265 1/10,000 to < 1/1,000); very rare (< 1/10,000 including isolated \nreports), not known (cannot be estimated from the available data). \n \n\nSystem organ class  Adverse reactions \nInfections and infestations Common: Pneumonia, herpes zoster, upper respiratory tract \n\ninfection, lower respiratory tract infection, oral candidiasis, oral \nfungal infection, urinary tract infection, herpes simplex, candida \ninfection; \nNot known: Infection, sepsis. \n\nBlood and the lymphatic system \ndisorders \n\nCommon: Neutropenia, anaemia, thrombocytopenia, lymphopenia, \nleukopenia, leukocytosis; \nUncommon: Febrile neutropenia, pancytopenia, coagulopathy. \n\nEndocrine disorders Common: Cushing\u2019s syndrome; \nUncommon: Hypothyroidism; \nNot known: Adrenal atrophy, steroid withdrawal syndrome, adrenal \ninsufficiency, hirsutism, menstrual irregularity.  \n\nMetabolism and nutrition \ndisorders \n\nVery common: Hyperglycaemia; \nCommon: Hypokalaemia, diabetes mellitus, anorexia, increased or \ndecreased appetite, hypoalbuminaemia, fluid retention, \nhyperuricaemia; \nUncommon: Dehydration, hypocalcaemia, hypomagnesemia; \nNot known: Glucose tolerance impaired, sodium retention, \nmetabolic alkalosis. \n\nPsychiatric disorders Very common: Insomnia; \nCommon: Depression, anxiety, aggression, confusional state, \nirritability, nervousness, mood alteration, agitation, euphoric mood; \nUncommon: Mood swings, hallucinations; \nNot known: Mania, psychosis, behavioural disturbance. \n\n\n\n11 \n\nNervous system disorders Common: Peripheral neuropathy, dizziness, psychomotor \nhyperactivity, disturbance in attention, memory impairment, \ntremor, paraesthesia, headache, ageusia, dysgeusia, somnolence, \nlethargy, balance impaired, dysphonia; \nUncommon: Cerebrovascular accident, transient ischaemic attack, \namnesia, coordination abnormal, ataxia, syncope; \nNot known: Convulsions. \n\nEye disorders Common: Vision blurred, cataract; \nUncommon: Conjunctivitis, increased lacrimation; \nNot known: Chorioretinopathy, glaucoma. \n\nEar and labyrinth disorders Common: Vertigo. \nCardiac disorders Common: Atrial fibrillation, supraventricular extrasystoles, \n\ntachycardia, palpitations; \nUncommon: Myocardial ischaemia, bradycardia; \nNot known: Congestive heart failure. \n\nVascular disorders Common: Venous thromboembolic reactions, predominantly deep \nvein thrombosis and pulmonary embolism, hypertension, \nhypotension, flushing, blood pressure increased, diastolic blood \npressure decreased; \nNot known: Purpura, bruising. \n\nRespiratory, thoracic, or \nmediastinal disorders \n\nCommon: Bronchitis, cough, dyspnoea, pharyngolaryngeal pain, \nhoarseness, hiccough.  \n\nGastrointestinal disorders Very Common: Constipation; \nCommon: Vomiting, diarrhoea, nausea, dyspepsia, stomatitis, \ngastritis, abdominal pain, dry mouth, abdominal distension, \nflatulence; \nNot known: Pancreatitis, gastrointestinal perforation, \ngastrointestinal haemorrhage, gastrointestinal ulcer. \n\nHepatobiliary disorders Common: Liver function tests abnormal, alanine aminotransferase \nincreased. \n\nSkin and subcutaneous tissue \ndisorders \n\nCommon: Rash, erythema, hyperhidrosis, pruritus, dry skin, \nalopecia; \nUncommon: Urticaria; \nNot known: Skin atrophy, acne. \n\nMusculoskeletal and connective \ntissue disorders \n\nVery common: Muscular weakness, muscle cramps; \nCommon: Myopathy, musculoskeletal pain, arthralgia, pain in \nextremity; \nNot known: Pathological fracture, osteonecrosis, osteoporosis, \ntendon rupture. \n\nRenal and urinary disorders Common: Pollakiuria; \nUncommon: Renal failure. \n\nGeneral disorders and \nadministration site conditions \n\nVery common: Fatigue, asthenia, oedema (including peripheral and \nfacial oedema); \nCommon: Pain, mucosal inflammation, pyrexia, chills, malaise; \nNot known: Impaired healing. \n\nInvestigations Common: Weight decreased, weight increased. \n \nDescription of selected adverse reactions \n \nPrior to the use of Neofordex in combination with any other medicinal product, reference should be \nmade to the Summary of Product Characteristics of that product.  \n \nThe incidence rate of certain adverse reactions varies depending on the combination treatment used.  \n \nThe combination of lenalidomide with dexamethasone in relapsed or refractory multiple myeloma patients is \nassociated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated \n\n\n\n12 \n\npatients compared with 0.6% in placebo/dexamethasone-treated patients). Grade 4 febrile neutropenia \nepisodes were observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to \n0.0% in placebo/dexamethasone treated patients). A similar incidence of high-grade neutropenia was \nreported in newly diagnosed patients treated with the combination of lenalidomide and dexamethasone. \n \nNeutropenia occurred in 45.3% of relapsed and refractory multiple myeloma patients who received low dose \ndexamethasone plus pomalidomide (Pom + LD-Dex), and in 19.5% of patients who received high dose \ndexamethasone (HD-Dex). Neutropenia was Grade 3 or 4 in 41.7% of patients who received Pom + LD-Dex, \ncompared with 14.8% who received HD-Dex. In Pom + LD-Dex treated patients neutropenia was \ninfrequently serious (2.0% of patients), did not lead to treatment discontinuation, and was associated with \ntreatment interruption in 21.0% of patients, and with dose reduction in 7.7% of patients. Febrile neutropenia \n(FN) was experienced in 6.7% of patients who received Pom + LD-Dex, and in no patients who received \nHD-Dex. All were reported to be Grade 3 or 4. FN was reported to be serious in 4.0% of patients. FN was \nassociated with dose interruption in 3.7% of patients, and with dose reduction in 1.3% of patients, and with \nno treatment discontinuations. \n \nThe combination of lenalidomide with dexamethasone in relapsed or refractory multiple myeloma patients is \nassociated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in \nlenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated \npatients). A similar incidence of high-grade thrombocytopenia was reported in newly diagnosed patients \ntreated with the combination of lenalidomide and dexamethasone. Thrombocytopenia occurred in 27.0% of \nrelapsed and refractory multiple myeloma patients who received Pom + LD-Dex, and 26.8% of patients who \nreceived HD-Dex. Thrombocytopenia was Grade 3 or 4 in 20.7% of patients who received Pom + LD-Dex \nand in 24.2% who received HD-Dex. In Pom + LD-Dex treated patients, thrombocytopenia was serious in \n1.7% of patients, led to dose reduction in 6.3% of patients, to dose interruption in 8% of patients and to \ntreatment discontinuation in 0.7% of patients. \n \nThe combination of lenalidomide, thalidomide or pomalidomide with dexamethasone is associated with an \nincreased risk of deep vein thrombosis and pulmonary embolism in patients with multiple myeloma (see \nsection 4.5). Concomitant administration of erythropoietic medicinal products or previous history of deep \nvein thrombosis may also increase thrombotic risk in these patients. \n \nLow-grade peripheral neuropathic reactions, predominantly grade 1 paraesthesia, may be observed with \ndexamethasone alone in up to 34% of newly diagnosed multiple myeloma patients. However, both incidence \nand severity of peripheral neuropathy increase with concomitant bortezomib or thalidomide administration. \nIn one study, 10.7% of patients treated with thalidomide and dexamethasone experienced grade 3/4 \nneuropathic reactions, compared to 0.9% of patients treated with dexamethasone alone. \n \nReporting of suspected adverse reactions \n \nReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows \ncontinued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked \nto report any suspected adverse reactions via the national reporting system listed in Appendix V. \n \n4.9 Overdose \n \nAcute toxicity of dexamethasone is weak and toxic effects have rarely been observed after an acute overdose. \nNo antidote exists and treatment is symptomatic. \n \n \n5. PHARMACOLOGICAL PROPERTIES \n \n5.1  Pharmacodynamic properties \n \nPharmacotherapeutic group: Corticosteroids for systemic use, glucocorticoids, ATC code: H02AB02 \n \n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\n\n\n13 \n\nMechanism of action \n \nDexamethasone is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low \nmineralocorticoid activity. At high doses (e.g. 40mg), it reduces the immune response. \n \nDexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of \nNuclear Factor-\u03baB activity and an activation of caspase-9 through second mitochondria-derived activator of \ncaspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve \nmaximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. \nDexamethasone also down-regulated anti apoptotic genes and increased I\u03baB-\u03b1 protein levels.  \n \nDexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and \nwith proteasome inhibitor (e.g. bortezomib).  \n \nMultiple myeloma is a progressive rare haematologic disease. It is characterized by excessive numbers of \nabnormal plasma cells in the bone marrow and overproduction of intact monoclonal immunoglobulin (IgG, \nIgA, IgD, or IgE) or Bence-Jones protein only (free immunoglobulin monoclonal \u03ba and \u03bb light chains). \n \nClinical efficacy and safety \n \nNo clinical efficacy and safety studies have been conducted using Neofordex in the treatment of multiple \nmyeloma. \n \nThe efficacy and safety of dexamethasone combination treatment in multiple myeloma has been confirmed \nin numerous clinical studies in newly diagnosed patients and in patients with relapsed or refractory disease. \nThe patient populations studied included a wide range of ages, as well as patients considered eligible or \nineligible for autologous stem cell transplantation. High-dose (40mg or 20mg) oral dexamethasone has been \nstudied in the therapy of multiple myeloma in combination with chemotherapy in the VAD regimen \n(vincristine, adriamycin/doxorubicin and dexamethasone) or in association with novel agents, including \nthalidomide and its analogues as well as proteasome inhibitors. In controlled studies, combination treatment \nwith dexamethasone consistently showed better outcomes in terms of survival and response than single-agent \ndexamethasone. \n \nPaediatric population \n \nThe European Medicines Agency has waived the obligation to submit the results of studies with Neofordex \nin all subsets of the paediatric population in multiple myeloma (see section 4.2 for information on paediatric \nuse). \n \n5.2 Pharmacokinetic properties \n \nAbsorption \n \nAfter oral administration of Neofordex, dexamethasone peak plasma levels are reached at a median of three \nhours. Bioavailability of dexamethasone is approximately 80%. There is a linear relationship between \nadministered and bioavailable doses.   \nDexamethasone is transported by the P-glycoprotein (also known as MDR1). Other MDR transporters may \nalso have a role in dexamethasone transport. \n \nDistribution \n \nDexamethasone is bound by plasma proteins, principally albumin, up to about 80%, depending on the \nadministered dose. At very high doses the majority of dexamethasone circulates unbound in the blood. The \nvolume of distribution is approximately 1 l/kg. Dexamethasone crosses the blood-brain barrier and the \nplacental barrier and passes into breast milk. \n \nBiotransformation \n\n\n\n14 \n\n \nA minor part of administered dexamethasone is excreted unchanged by the kidney. The major part is \nhydrogenated or hydroxylated in humans, the major metabolites being hydroxy-6-dexamethasone and \ndihydro-20-dexamethasone. 30 to 40% are conjugated to glucuronic acid or sulphated in the human liver and \nexcreted in this form in the urine. Dexamethasone is metabolized via cytochrome P450 3A4 (CYP3A4). \nOther cytochrome P450 isoenzymes may also play a role in dexamethasone biotransformation. \n \nElimination \n \nThe plasma half-life of dexamethasone is approximately 250 minutes.  \n \nSpecific groups of patients \n \nNo data are available on the biotransformation of dexamethasone in hepatically impaired patients. \n \nSmoking has no influence on dexamethasone pharmacokinetics. No differences were found in \ndexamethasone pharmacokinetics between subjects of European and Asian (Indonesian and Japanese) \ndescent. \n \n5.3 Preclinical safety data \n \nGlucocorticoids have only weak acute toxicity. No chronic toxicity and carcinogenicity data are available. \nGenotoxicity findings have been shown to be artefactual. In reproductive toxicity studies in mice, rats, \nhamsters, rabbits and dogs, dexamethasone has led to embryo-fetal malformations such as increase in cleft \npalate and skeletal defects; decreases in thymus, spleen and adrenal weight; lung, liver, and kidney \nabnormalities; and inhibition of growth. Post-natal development assessment of animals treated prenatally \npresented decreased glucose tolerance and insulin sensitivity, behavioural alterations and decrease in brain \nand body weight. In males, fertility may be decreased through germ cell apoptosis and spermatogenic \ndefects. Data on female fertility are contradictory. \n \n \n6. PHARMACEUTICAL PARTICULARS \n \n6.1 List of excipients \n \nLactose monohydrate \nMicrocrystalline cellulose \nMagnesium stearate \nColloidal anhydrous silica \n \n6.2 Incompatibilities \n \nNot applicable. \n \n6.3 Shelf life \n \n3 years. \n \n6.4 Special precautions for storage \n \nThis medicinal product does not require any special temperature storage conditions. \n \nTablets should be kept in the blister package until administration. Individual tablets in intact packaging \nshould be separated from the blister using the perforation, e.g. for use in multi-compartment compliance aids. \nHalved tablets that are not taken immediately should be disposed of (see section 6.6).  \n \n\n\n\n15 \n\n6.5 Nature and contents of container  \n \n10 x 1 tablets in OPA/Aluminium /PVC-Aluminium perforated unit dose blister.  \n \nPack size of 10 tablets. \n \n6.6 Special precautions for disposal  \n \nAny unused medicinal product or waste material should be disposed of in accordance with local \nrequirements. Advise patients to not dispose of unused tablets through household waste or wastewater. \n \n \n7. MARKETING AUTHORISATION HOLDER \n \nLaboratoires CTRS \n63, rue de l\u2019Est \n92100 Boulogne-Billancourt \nFrance \nEmail: ctrs@ctrs.fr \n \n \n8. MARKETING AUTHORISATION NUMBER(S)  \n \nEU/1/15/1053/001 \n \n \n9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION \n \nDate of first authorisation: 16 March 2016 \nDate of latest renewal: \n \n \n10. DATE OF REVISION OF THE TEXT \n \nDetailed information on this medicinal product is available on the website of the European Medicines \nAgency http://www.ema.europa.eu. \n \n  \n\nhttp://www.ema.europa.eu/\n\n\n16 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \n\nANNEX II \n \n\nA. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE  \n \n\nB. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY \nAND USE \n \n\nC. OTHER CONDITIONS AND REQUIREMENTS OF THE \nMARKETING AUTHORISATION \n \n\nD. CONDITIONS OR RESTRICTIONS WITH REGARD TO \nTHE SAFE AND EFFECTIVE USE OF THE MEDICINAL \nPRODUCT \n\n\n\n17 \n\nA. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE \n \nName and address of the manufacturer responsible for batch release \n \nLaboratoires CTRS \n63, rue de l\u2019Est \n92100 Boulogne-Billancourt \nFrance \n \n \nB. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE \n \nMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product \nCharacteristics, section 4.2). \n \n \nC. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION  \n \n\u2022 Periodic safety update reports (PSURs) \n \nThe requirements for submission of PSURs for this medicinal product are set out in the list of Union \nreference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent \nupdates published on the European medicines web-portal. \n \n \nD. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE \n\nOF THE MEDICINAL PRODUCT \n \n\u2022 Risk management plan (RMP) \n \nThe marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and \ninterventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any \nagreed subsequent updates of the RMP. \n \nAn updated RMP should be submitted: \n\n\u2022 At the request of the European Medicines Agency; \n\u2022 Whenever the risk management system is modified, especially as the result of new information being \n\nreceived that may lead to a significant change to the benefit/risk profile or as the result of an \nimportant (pharmacovigilance or risk minimisation) milestone being reached.  \n\n  \n\n\n\n18 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nANNEX III \n \n\nLABELLING AND PACKAGE LEAFLET \n  \n\n\n\n19 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nA. LABELLING \n  \n\n\n\n20 \n\nPARTICULARS TO APPEAR ON THE OUTER PACKAGING \n \nOUTER CARTON \n \n \n1. NAME OF THE MEDICINAL PRODUCT \n \nNeofordex 40 mg tablets  \ndexamethasone \n \n \n2. STATEMENT OF ACTIVE SUBSTANCE(S) \n \nEach tablet contains dexamethasone acetate equivalent to 40 mg dexamethasone. \n \n \n3. LIST OF EXCIPIENTS \n \nContains lactose. See package leaflet for further information. \n \n \n4. PHARMACEUTICAL FORM AND CONTENTS \n \n10 x 1 tablets \n \n \n5. METHOD AND ROUTE(S) OF ADMINISTRATION \n \nRead the package leaflet before use. \nOral use \n \n \n6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF \n\nTHE SIGHT AND REACH OF CHILDREN \n \nKeep out of the sight and reach of children. \n \n \n7. OTHER SPECIAL WARNING(S), IF NECESSARY \n \n \n8. EXPIRY DATE \n \nEXP \n \n \n9. SPECIAL STORAGE CONDITIONS \n \n \n10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR \nWASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE \n \n \n\n\n\n21 \n\n11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER \n \nLaboratoires CTRS \n63, rue de l\u2019Est \n92100 Boulogne-Billancourt \nFrance \nEmail: ctrs@ctrs.fr \n \n \n12. MARKETING AUTHORISATION NUMBER(S)  \n \nEU/1/15/1053/001  \n \n \n13. BATCH NUMBER \n \nLOT \n \n \n14. GENERAL CLASSIFICATION FOR SUPPLY \n \n \n15. INSTRUCTIONS ON USE \n \n \n16. INFORMATION IN BRAILLE \n \nneofordex \n17. UNIQUE IDENTIFIER \u2013 2D BARCODE \n \n2D barcode carrying the unique identifier included. \n \n \n18. UNIQUE IDENTIFIER - HUMAN READABLE DATA \n \nPC  \nSN  \nNN  \n \n \n  \n\n\n\n22 \n\nMINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS \n \nBLISTER \n \n \n1. NAME OF THE MEDICINAL PRODUCT \n \nNeofordex 40 mg tablet  \ndexamethasone \n \n \n2. NAME OF THE MARKETING AUTHORISATION HOLDER \n \nLaboratoires CTRS \n \n \n3. EXPIRY DATE \n \nEXP \n \n \n4. BATCH NUMBER \n \nLot \n \n \n5. OTHER \n \n \n  \n\n\n\n23 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nB. PACKAGE LEAFLET \n\n\n\n24 \n\nPackage leaflet: Information for the patient \n \n\nNeofordex 40 mg tablet \ndexamethasone \n\n \nRead all of this leaflet carefully before you start taking this medicine because it contains important \ninformation for you. \n- Keep this leaflet. You may need to read it again.  \n- If you have any further questions, ask your doctor or pharmacist. \n- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if \n\ntheir signs of illness are the same as yours.  \n- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects \n\nnot listed in this leaflet. See section 4. \n \nWhat is in this leaflet \n1. What Neofordex is and what it is used for  \n2. What you need to know before you take Neofordex \n3. How to take Neofordex \n4. Possible side effects  \n5. How to store Neofordex \n6. Contents of the pack and other information \n \n \n1. What Neofordex is and what it is used for \n \nNeofordex is a medicine that contains the active substance dexamethasone. Dexamethasone is a type of \nhormone called a glucocorticoid, sometimes called a corticoid or corticosteroid, with various actions \nincluding effects on white blood cells, which form part of the immune system (the body\u2019s natural defences). \nDexamethasone is similar to glucocorticoids which are naturally produced in the body. \n \nNeofordex is used to treat adult patients with multiple myeloma, a cancer of the blood affecting the white \nblood cells that produce antibodies. Neofordex will be given in combination with other medicines for \nmultiple myeloma. They act together by killing cancerous white blood cells. \n \n \n2. What you need to know before you take Neofordex \n \nDo not take Neofordex \n\u2212 if you are allergic to dexamethasone or any of the other ingredients of this medicine (listed in section 6); \n\u2212 if you have a viral infection, especially viral hepatitis, herpes, chickenpox or shingles; \n\u2212 if you have an untreated psychiatric illness. \n \nWarnings and precautions  \nTalk to your doctor, pharmacist, nurse, before taking Neofordex especially if given with other medicinal \nproducts. \n \nRisk of infection \nTreatment with Neofordex (a high-dose corticosteroid) may reduce your body\u2019s ability to fight infection (in \nparticular due to bacteria, yeasts and/or parasites). This can sometimes lead to infections caused by germs \nthat rarely cause infection under normal circumstances (called opportunistic infections). If you get an \ninfection of any kind during treatment with this medicine, contact your doctor immediately. This is \nparticularly important if you notice signs of pneumonia: cough, fever, shortness of breath and chest pain. \nYou may also feel confused, particularly if you are elderly. You should also tell your doctor if you have had \ntuberculosis or if you have stayed in regions where roundworm infections are common.  \n \n\n\n\n25 \n\nNote: It is important that while you are taking Neofordex you avoid contact with anyone who is suffering \nfrom chickenpox, measles or shingles. If you think you may have had contact with anyone with these \nconditions, you should inform your doctor immediately.  \n \nPsychiatric disorders \nHigh-dose corticosteroids, including dexamethasone, can cause psychological problems that may sometimes \nbe serious. Talk to your doctor before taking Neofordex if you or a member of your immediate family have \nsuffered, or currently suffer from severe depression or manic attacks. This is especially important if you feel \ndepressed or might be thinking about suicide. Insomnia may be minimised by administering Neofordex in \nthe morning. \n \nTumour lysis syndrome \nYou should tell your doctor if you have symptoms of tumour lysis syndrome such as muscle cramping, \nmuscle weakness, confusion, visual loss or disturbances and shortness of breath \n \nLong-term treatment \nDuring treatment with this medicine it is important to maintain a balanced diet (low in sugar and sodium, \nhigh in protein). Water and sodium retention is common and can lead to hypertension.  \nYour doctor will advise on an appropriate diet, and may prescribe potassium, calcium or vitamin D \nsupplements. \n \nGlucocorticoid therapy like dexamethasone may reduce the effect of medicines to treat diabetes or \nhypertension. The dose of these medicines may have to be increased by your doctor. \n \nHaematology  \nIf you have had blood clots in the past you should inform your doctor before taking Neofordex. The \ncombination of dexamethasone with thalidomide, lenalidomide or pomalidomide (medicines to treat multiple \nmyeloma) increases the risk of blood clots in the veins and arteries. You must tell your doctor immediately if \nyou experience shortness of breath, chest pain or swelling in the arms or legs. \n \nThe combination of dexamethasone with lenalidomide or pomalidomide may cause a decrease in normal \nwhite blood cells (blood cells that help fight infection) and/or blood platelets (which help prevent bleeding). \nYour doctor will arrange appropriate blood tests before and during treatment.  \n \nPheochromocytoma crisis  \nTreatment with this medicine may cause pheochromocytoma crisis, which can be fatal. Pheochromocytoma \nis a rare tumor of the adrenal glands Crisis can occur with the following symptoms: headaches, sweating, \npalpitations, and hypertension. Contact your doctor immediately if you experience any of these signs. \n \nEye disorders \nTreatment with this medicine may cause central serous chorioretinopathy, an eye disease that leads to blurred \nor distorted vision. This happens usually in one of the eyes. If you notice blurring or distorted vision that \nlasts for several days, please contact your doctor. \n \nTendonitis  \nTreatment with this medicine may cause tendon inflammation. In extremely rare cases, a tendon may \nrupture. This risk is increased by treatment with certain antibiotics and by kidney problems. Contact your \ndoctor if you notice painful, stiff or swollen joints or tendons. \n \nPlease inform any doctor, dentist or person who may prescribe a treatment for you that you are currently \ntaking or have recently taken dexamethasone (see section \u201cOther medicines and Neofordex\u201d). \n \nIf you become ill or are involved in an accident, or if you need surgery (even at the dentist) or require a \nvaccination (high dose of glucocorticoid may diminish the effect of \u201clive virus\u201d vaccines) you should inform \nthe doctor treating you that you are taking or have recently taken high-dose corticosteroids. \n \n\n\n\n26 \n\nIf you need tests (in particular for infections) you should inform the person performing the tests as \ndexamethasone may interfere with the results. \n \nTalk to your doctor before taking Neofordex \n- if you have liver or kidney disease, \n- if you have heart disease or you have recently had a heart attack, \n- if you have high blood pressure, high cholesterol or you are a smoker, \n- if you have diabetes or if there is a history of diabetes in your family, \n- if you have osteoporosis, especially if you are a woman who has been through the menopause, \n- if you have glaucoma (increased eye pressure) or if there is a history of glaucoma in your family, \n- if you have myasthenia gravis (a disease affecting the muscles), inflammation of a tendon (tendonitis), \n- if you have a peptic ulcer (ulcer in your stomach or duodenum), or a history of peptic ulcers, stomach \n\nbleeding or perforation, \n- if you have inflammation of the colon, diverticulitis, or have recently had surgery on the intestine,  \n- if you have or are suspected of having pheochromocytoma (a tumor of the adrenal glands). \n \nYou doctor will observe you more closely if you have any of the listed diseases. \n \nElderly \nIf you are elderly, some of the side effects of Neofordex may be more serious, especially thinning of the \nbones (osteoporosis), high blood pressure, low potassium levels, diabetes, susceptibility to infection and \nthinning of the skin. Your doctor will monitor you more closely. \n \nChildren and adolescents \nChildren do not develop multiple myeloma. This medicine should not be given to children (i.e. anyone below \nthe age of 18 years). \n \nOther medicines and Neofordex \nTell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. \n \nYou must read the package leaflets of all medicines to be taken in combination with Neofordex for \ninformation related to these medicines before starting treatment with Neofordex. When thalidomide, \nlenalidomide or pomalidomide is used, particular attention to pregnancy testing and prevention requirements \nis needed. \n \nIf you are taking any of the following medicines, you should consult your doctor before taking Neofordex: \n \nThe following combinations should be avoided \n- Acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever (may \n\nincrease the risk of bleeding);  \n- You should also tell your doctor if you have recently received a vaccination or are planning to be \n\nvaccinated (please see section \u201cWarnings and precautions\u201d). \n \nThe following combinations require precautions  \n- Medicines that reduce blood potassium levels: for example, some diuretics or laxatives, amphotericin B \n\ninjection, tetracosactide, due to the risk of decreased potassium levels. Your doctor may need to monitor \nthe level of potassium; \n\n- Medicines that can increase the risk of abnormal heart rhythm (e.g. some medicines for treatment \nof heart disease, as digitalis), since low levels of potassium increase the risk of abnormal heart beats; \n\n- Medicines to treat hypertension, since their effect can be reduced. Your doctor may need to adjust the \ndose of anti-hypertensive treatment; \n\n- Medicines to treat anaemia such as Erythropoietin (EPO) or other medicines such as hormone \nreplacement therapy, may increase the risk of formation of blood clots (please see sections \u201cWarnings \nand precautions\u201d and \u201cPossible side effects\u201d); \n\n- Medicines to treat pain, inflammation and fever (non-steroidal anti-inflammatory drugs) e.g. ibuprofen, \nnaproxen, diclofenac, meloxicam and others may increase the risk of bleeding or open sores in the \nstomach; \n\n\n\n27 \n\n- Medicines for treatment of diabetes, as Neofordex can modify glucose level. It is important to self-\nmonitor blood glucose levels, especially during the initiation of treatment. Your doctor may need to \nadjust the dose of anti-diabetic medicines; \n\n- Some antibiotics (such as fluoroquinolones) may increase the risk of tendonitis and, in exceptional cases, \nrupture of the affected tendon, particularly after long-term treatment; \n\n- Certain medicines to treat cancer (such as methotrexate) may increase the risk of infection, bleeding or \nanaemia. \n\n \nThe following medicines may influence the effect of Neofordex  \nThese medicines may reduce the effect of Neofordex:  \n- Aminogluthetimide (medicine to treat Cushing\u2019s syndrome or breast cancer); \n- Anticonvulsants (for the treatment of epilepsy) such as carbamazepine, fosphenytoin, phenobarbital, \n\nphenytoin, primidone; \n- Rifampicin (used to treat tuberculosis); \n- Medicines for an upset stomach (for example antacids) as well as colestyramine (to lower cholesterol); \n\nThe administration of such medicines with Neofordex should be separated by at least two hours; \n- Ephedrine (to treat asthma attacks or relieve nasal congestion). \nThese medicines may increase the effect of Neofordex: \n- Aprepitant or fosaprepitant (for the treatment of nausea and vomiting after surgery or caused \n\nby chemotherapy [cancer treatment]); \n- Antibiotics, with active substance names ending in \u2013mycin and antifungals (to treat fungal infections) \n\nwith active substance names ending in \u2013conazole; and anti-HIV medicines with active substance \nnames ending in \u2013navir.  \n\n \nNeofordex may influence the effect of these medicines \n- The effect of oral contraceptives and hormone replacement therapy (HRT) may be reduced. Effective \n\nmeasures to avoid pregnancy must be taken (see section \u201cPregnancy, breast-feeding and fertility\u201d); \n- The effect of oral anticoagulants may be increased, leading to increased bleeding risk. Your doctor may \n\nneed to monitor closely your blood coagulation parameters; \n- The effect of certain medicines to treat cancer (such as docetaxel and cyclophosphamide) may be \n\nreduced; \n- The liver effects of lapatinib (used to treat cancer) may be increased; \n- The effect of ciclosporin (a medicine used to suppress immune reactions) may be reduced. In addition, \n\nconvulsions have been reported with concurrent use of dexamethasone and ciclosporin. Concomitant use \nof Neofordex and ciclosporine should be avoided; \n\n- The effect of midazolam (used as sleeping pill and for the treatment of epilepsy) may be reduced; \n- The effect of ivermectin (for certain worm infections) may be reduced, therefore the treatment with \n\nivermectin must be successfully terminated before Neofordex administration (see section \u201cWarnings and \nprecautions\u201d); \n\n- The effect of rifabutin or isoniazid (used to treat tuberculosis) may be reduced; \n- The effect of indinavir (used in the treatment of HIV) may be reduced;  \n- The effect of erythromycin may be reduced; \n- The effect of praziquantel (for certain worm infections) may be reduced with a risk of failure \n\nof treatment, therefore treatment with praziquantel and Neofordex should be separated by at least one \nweek. \n\n \nPregnancy, breast-feeding and fertility \nIf you are pregnant or breast-feeding, you think you may be pregnant or are planning to have a baby, ask \nyour doctor or pharmacist for advice before taking this medicine. \n \nYou must avoid getting pregnant during treatment with Neofordex which may cause congenital \nmalformations. You and your partner must use appropriate contraception.  \nYou should not use Neofordex during pregnancy unless your clinical condition requires treatment with \ndexamethasone. Inform your doctor immediately if you are pregnant or if you become pregnant during \ntreatment.  \n \n\n\n\n28 \n\nGlucocorticoids are excreted in human milk, therefore, a risk to the newborns/infants cannot be excluded. \nTell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether \nto stop breast-feeding, or whether to stop taking Neofordex, considering the benefit of breast-feeding to the \nbaby and the benefit of Neofordex to the mother.  \n \nDriving and using machines \nNeofordex has moderate influence on the ability to drive and use machines. Do not drive, use any tools or \nmachines or carry out any hazardous tasks if you experience side effects, such as confusion, hallucinations, \ndizziness, tiredness, sleepiness, fainting or blurred vision.   \n \nNeofordex contains lactose \nNeofordex contains lactose, a sugar. If you have been told by your doctor that you have intolerance to some \nsugars, contact your doctor before taking this medicine. \n \n \n3. How to take Neofordex \n \nAlways take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.  \n \nYour doctor will decide the dose and how often you should take Neofordex. This can vary according to your \ncondition and to other associated treatment(s). The recommended dose is one tablet each time. If you are \nover 65 years old and/or frail, your doctor may prescribe a half tablet each time. Do not exceed or take less \nthan the prescribed dose. You must take this medicine on the appropriate days, exactly as your doctor \nprescribed. \n \nYour doctor may change the dose and frequency of administration based on certain parameters including \nyour blood analyses, your general condition, other medicines prescribed to you and your response to the \ntreatment.  \n \nSwallow the prescribed dose of one tablet (40 mg) or half a tablet (20 mg) in the morning with a glass of \nwater.  \n \nIf your dose is half a tablet (20 mg), the tablet should be divided into two equal halves using the score line. \nTake one half tablet straightaway. Do not save the spare half tablet to take on another day as this \nmedicine may deteriorate once divided and taken out of its packaging. Then, keep the spare half tablet \nin a safe place, out of the sight and reach of children, until you can throw it away properly, as you should not \nthrow away any medicines in wastewater or household waste. Ask your pharmacist how to throw them away. \nIf you have difficulties taking the tablet out of the blister or breaking the tablet, ask somebody for help.  \nInsomnia may be minimised by administering Neofordex in the morning. \n \nIf you take more Neofordex than you should \nIf you take too much Neofordex contact your doctor or hospital immediately. \n \nIf you forget to take Neofordex \nIf you forget to take Neofordex at the usual time and \n\n\u2013 if you are less than 12 hours late: take the tablet immediately. \n\u2013 if you are more than 12 hours late: do not take the tablet but take the next tablet at the usual time.  \n\n \nDo not take a double dose to make up for a forgotten tablet. \n \nIf you stop taking Neofordex \nYou may experience serious side effects if you stop taking this medicine suddenly. If you stop taking this \nmedicine too quickly, you may have low blood pressure. You may also feel a \u2018withdrawal symptom\u2019. This \nmay include headache, problems with your vision (including pain or swelling in the eye), feeling or being \nsick, fever, pain in your muscles and joints, swelling in the inside of your nose, weight loss, itchy skin and \nconjunctivitis. If your treatment is to be stopped follow your doctor\u2019s advice.  \n \n\n\n\n29 \n\nIf you have any further questions on the use of this medicine, ask your doctor or pharmacist. \n \n \n4. Possible side effects \n \nLike all medicines, this medicine can cause side effects, although not everybody gets them. \n \nYour doctor will discuss these with you and will explain the potential risks and benefits of your treatment.  \n \nThe side effects listed below were seen when dexamethasone was taken for the treatment of multiple \nmyeloma and for the treatment of other diseases. In some cases, the combination of several medicines can \nincrease the side effects of one or the other of these medicines taken separately.  \n \nNeofordex may cause serious mental health problems. These are common (may affect up to 1 in 10 people) \nand may include: \n\n- feeling depressed (including thinking about suicide) \n- feeling high (mania), very happy (euphoria) or moods that go up and down, \n- feeling anxious, having difficulty in concentrating and memory loss, \n- feeling, seeing or hearing things that do not exist or believing in things that are not real, having \n\ngloomy thoughts, changing how you act. \nIf you notice any of these symptoms talk to a doctor straight away. \n \nOther possible side effects may be: \nVery common: may affect more than 1 in 10 people \n\u2212 Increased blood sugar levels (hyperglycaemia); \n\u2212 Constipation; \n\u2212 Having trouble sleeping (insomnia); \n\u2212 Muscle cramps, muscle weakness; \n\u2212 Tiredness, weakness, swelling of the body and face. \nCommon: may affect up to 1 in 10 people \n\u2212 Bacterial, viral or fungal infections, including pneumonia, shingles, infections of the nose, mouth, tonsils \n\nor throat, bronchitis, herpes, bladder infection, candida infection; \n\u2212 Reduction in the number of red or white blood cells and/or platelets, or increased number of white blood \n\ncells, decreased levels of potassium or of albumin (a protein) in the blood, increased levels of uric acid in \nthe blood, changes in liver function tests;  \n\n\u2212 Cushing\u2019s syndrome, i.e. weight gain of the trunk and face, excessive sweating, stretch marks, visible \nswollen capillaries (small blood vessels) and dryness of the skin, growth of extra facial hair (especially \nin women) and thinning of the hair;  \n\n\u2212 Development of diabetes, loss or increase of appetite, weight gain or weight loss, water retention;  \n\u2212 Aggression, confusion, irritability, nervousness, restlessness, altered mood; \n\u2212 Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet due to nerve \n\ndamage, dizziness, trembling, headache, loss of or change in the sense of taste;  \n\u2212 Cataract, blurred vision; \n\u2212 Fast or irregular heart rhythm, too high or too low blood pressure, formation of blood clots that may clog \n\nblood vessels (for example in legs or lungs), swelling of arms or legs, reddening of the skin of the face or \nbody;  \n\n\u2212 Cough, breathing difficulties, difficulties speaking, sore throat or mouth, hoarseness, dry mouth, \nhiccough, inflammation of the mucous membranes; \n\n\u2212 Vomiting, nausea, diarrhoea, indigestion, bloating, swollen and/or painful stomach; \n\u2212 Rash, itching, reddened skin, excessive sweating (hyperhidrosis), dry skin, hair loss (alopecia); \n\u2212 Muscle wasting, pain of the muscles, joints, bones or limbs; \n\u2212 Frequent urination; \n\u2212 Pain, fever, chills, fainting, vertigo, exhaustion, drowsiness, impaired sense of balance.  \nUncommon: may affect up to 1 in 100 people \n\u2212 Fever due to a lack of certain white blood cells, lack of all types of blood cells, diminished blood \n\nclotting,; \n\n\n\n30 \n\n\u2212 Failure of the thyroid gland to produce normal amounts of hormones (hypothyroidism);  \n\u2212 Lack of body water (dehydration) with thirst or headache, decreased magnesium or calcium levels in the \n\nblood; \n\u2212 Mood swings, hallucinations; \n\u2212 Stroke, difficulties in coordination or movement, fainting; \n\u2212 Inflammation of the eye and/or eyelids, increased tearing; \n\u2212 Heart attack, abnormally slow heartbeat; \n\u2212 Hives; \n\u2212 Failure of the kidneys. \nNot known: frequency cannot be estimated from the available data \n\u2212 Infection, inflammation of the whole body due to infection (sepsis); \n\u2212 Inability of the body to respond normally to severe stress such as accidents, surgery or illness due to \n\ninsufficient function of the adrenal glands, severe unusual headache with visual disturbances linked to \nthe withdrawal of treatment, irregularity of menstrual cycles in women, excessive hair growth \n(hirsutism); \n\n\u2212 Increased need for diabetes medicine, salt imbalance, potassium loss due to low carbon dioxide levels (a \ncondition called metabolic alkalosis); \n\n\u2212 Epileptic fits;  \n\u2212 Increased pressure in the eye including glaucoma, choroid and retinal disorders (chorioretinopathy); \n\u2212 Inability of the heart to pump enough blood round the body (heart failure); \n\u2212 Ulcers, perforations and/or bleeding in the oesophagus (gullet), stomach or intestine, inflamed pancreas \n\n(which may show as pain in the back and abdomen); \n\u2212 Slow wound healing, acne, thinning of the skin, bruising, red or purple discolorations on the skin \n\n(purpura); \n\u2212 Thinning of the bones with increased risk of fracture, bone disease, ruptured tendon. \n \nReporting of side effects \nIf you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed \nin this leaflet. You can also report side effects directly via the national reporting system listed in Appendix \nV. By reporting side effects you can help provide more information on the safety of this medicine. \n \n \n5. How to store Neofordex \n \nKeep this medicine out of the sight and reach of children. \n \nDo not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry \ndate refers to the last day of that month. \n \nDo not use this medicine if you notice any defects, or any signs of deterioration of the tablets or packaging. \n \nThis medicine does not require any special temperature storage conditions. Keep tablets in the blister \npackaging until you take them. If you are using a pill organiser box, use the perforation to separate individual \ntablets from the blister without opening the packaging. \n \nThrow away half tablets that you have not taken. Do not throw away any medicines via wastewater or \nhousehold waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will \nhelp protect the environment. \n \n \n6. Contents of the pack and other information \n \nWhat Neofordex contains  \n- The active substance is dexamethasone. Each tablet contains dexamethasone acetate equivalent to \n\n40 mg dexamethasone. \n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\nhttp://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\n\n\n31 \n\n- The other ingredients are lactose monohydrate, microcrystalline cellulose, magnesium stearate and \ncolloidal anhydrous silica (see section 2).  \n\n \nWhat Neofordex looks like and contents of the pack \nEach tablet is white, oblong in shape, with a score line on one face. The tablet can be divided into two equal \nhalves.  \n \nEach carton contains 10 x 1 tablets in OPA/Aluminium /PVC-Aluminium perforated unit dose blister.  \n \nMarketing Authorisation Holder and Manufacturer \n \n \nLaboratoires CTRS \n63, rue de l\u2019Est  \n92100 Boulogne-Billancourt \nFrance \n \n \n \nFor any information about this medicine, please contact the local representative of the Marketing \nAuthorisation Holder: \n \nBelgi\u00eb/Belgique/Belgien \nLaboratoires CTRS \nT\u00e9l/Tel: +32 (0)2 40 11 442 \nctrs@ctrs.fr  \n \n\nLietuva \nImmedica Pharma AB  \nTel/Puh: +46 (0)8 533 39 500  \ninfo@immedica.com  \n\n\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f \nLaboratoires CTRS \nTe\u043b.: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n \n\nLuxembourg/Luxemburg \nLaboratoires CTRS \nT\u00e9l/Tel: +352 278 62 329 \nctrs@ctrs.fr  \n \n\n\u010cesk\u00e1 republika \nLaboratoires CTRS \nTe\u043b.: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n \n\nMagyarorsz\u00e1g \nLaboratoires CTRS \nTe\u043b.: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n\nDanmark \nImmedica Pharma AB  \nTlf: +46 (0)8 533 39 500  \ninfo@immedica.com  \n\nMalta \nLaboratoires CTRS \nTel: +356 2776 1358 \nctrs@ctrs.fr  \n \n\nDeutschland \nLaboratoires CTRS \nTel: +49 (0)3022153008 \nctrs@ctrs.fr  \n \n\nNederland \nLaboratoires CTRS \nTel: +31 (0)2 070 38 155 \nctrs@ctrs.fr  \n \n\nEesti \nImmedica Pharma AB  \nTel/Puh: +46 (0)8 533 39 500  \ninfo@immedica.com  \n\nNorge \nImmedica Pharma AB  \nTel/Puh: +46 (0)8 533 39 500  \ninfo@immedica.com  \n \n\n\u0395\u03bb\u03bb\u03ac\u03b4\u03b1 \nRAFARM AEBE \n\u03a4\u03b7\u03bb: + 302 106776550 \n  \n\n\u00d6sterreich \nLaboratoires CTRS \nTel: +43 (0)7 208 16 847 \nctrs@ctrs.fr  \n \n\nmailto:ctrs@ctrs.fr\nmailto:info@immedica.com\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:info@immedica.com\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:info@immedica.com\nmailto:info@immedica.com\nmailto:ctrs@ctrs.fr\n\n\n32 \n\nEspa\u00f1a \nLaboratoires CTRS \nTel: + 34 914 146 613 \nctrs@ctrs.fr  \n \n\nPolska \nLaboratoires CTRS \nTel.: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n \n\nFrance \nLaboratoires CTRS \nT\u00e9l: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n \n\nPortugal \nLaboratoires CTRS \nTel: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n \n\nHrvatska \nLaboratoires CTRS \nTel: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n \nIreland \nAspire Pharma Ltd \nTel: +44(0)1730 231148  \n\nRom\u00e2nia \nLaboratoires CTRS \nTel: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n \nSlovenija \nLaboratoires CTRS \nTel: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr  \n \n\n\u00cdsland \nImmedica Pharma AB  \nS\u00edmi: + 46 (0)8 533 39 500 \ninfo@immedica.com  \n\nSlovensk\u00e1 republika \nLaboratoires CTRS \nTe\u043b.: + 33 (0)1 70 76 06 37 \nctrs@ctrs.fr \n   \n\n \nItalia \nLaboratoires CTRS \nTel: + 39 (0)687 501302 \nctrs@ctrs.fr  \n\n \nSuomi/Finland \nImmedica Pharma AB  \nTel/Puh: +46 (0)8 533 39 500  \ninfo@immedica.com  \n\n \n\u039a\u03cd\u03c0\u03c1\u03bf\u03c2 \nRAFARM AEBE \n\u03a4\u03b7\u03bb: + 302 106776550 \n\n \nSverige \nImmedica Pharma AB  \nTel: +46 (0)8 533 39 500  \ninfo@immedica.com  \n\n \nLatvija \nImmedica Pharma AB  \nTel: +46 (0)8 533 39 500  \ninfo@immedica.com \n   \n\n \nUnited Kingdom \nAspire Pharma Ltd \nTel: +44(0)1730 231148 \n \n\n  \n \nThis leaflet was last revised in \n \nOther sources of information \n \nDetailed information on this medicine is available on the European Medicines Agency web site: \nhttp://www.ema.europa.eu.  \n \n \n \n \n\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:info@immedica.com\nmailto:ctrs@ctrs.fr\nmailto:ctrs@ctrs.fr\nmailto:info@immedica.com\nmailto:info@immedica.com\nmailto:info@immedica.com\nhttp://www.ema.europa.eu/\n\n\tSUMMARY OF PRODUCT CHARACTERISTICS\n\tA. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE\n\tB. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE\n\tC. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION\n\tD. CONDITIONS OR RESTRICTIONS\n\tA. LABELLING\n\tB. PACKAGE LEAFLET", "Section_1": {"Title": "1. what neofordex is and what it is used for", "Section_Content": "neofordex is a medicine that contains the active substance dexamethasone. dexamethasone is a type of hormone called a glucocorticoid, sometimes called a corticoid or corticosteroid, with various actions including effects on white blood cells, which form part of the immune system (the body's natural defences). dexamethasone is similar to glucocorticoids which are naturally produced in the body. neofordex is used to treat adult patients with multiple myeloma, a cancer of the blood affecting the white blood cells that produce antibodies. neofordex will be given in combination with other medicines for multiple myeloma. they act together by killing cancerous white blood cells.", "Entity_Recognition": [{"Text": "neofordex", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Id": 2, "BeginOffset": 0, "EndOffset": 9, "Score": 0.3927250802516937, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "a medicine", "Type": "TREATMENT", "BeginOffset": 13, "EndOffset": 23}, {"Text": "the active substance dexamethasone", "Type": "TREATMENT", "BeginOffset": 38, "EndOffset": 72}, {"Id": 4, "BeginOffset": 74, "EndOffset": 87, "Score": 0.9997548460960388, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 13, "BeginOffset": 101, "EndOffset": 132, "Score": 0.20485447347164154, "Text": "hormone called a glucocorticoid", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "a corticoid or corticosteroid", "Type": "TREATMENT", "BeginOffset": 151, "EndOffset": 180}, {"Id": 15, "BeginOffset": 224, "EndOffset": 241, "Score": 0.5767410397529602, "Text": "white blood cells", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 0, "BeginOffset": 266, "EndOffset": 279, "Score": 0.530434787273407, "Text": "immune system", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 8, "BeginOffset": 311, "EndOffset": 324, "Score": 0.998898983001709, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 9, "BeginOffset": 339, "EndOffset": 354, "Score": 0.5917297005653381, "Text": "glucocorticoids", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 1, "BeginOffset": 391, "EndOffset": 395, "Score": 0.35016223788261414, "Text": "body", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 10, "BeginOffset": 444, "EndOffset": 460, "Score": 0.6483985781669617, "Text": "multiple myeloma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9798012971878052}]}, {"Text": "a cancer", "Type": "PROBLEM", "BeginOffset": 462, "EndOffset": 470}, {"Text": "the blood", "Type": "PROBLEM", "BeginOffset": 474, "EndOffset": 483}, {"Text": "the white blood cells", "Type": "TEST", "BeginOffset": 494, "EndOffset": 515}, {"Text": "antibodies", "Type": "PROBLEM", "BeginOffset": 529, "EndOffset": 539}, {"Text": "neofordex", "Type": "TREATMENT", "BeginOffset": 541, "EndOffset": 550}, {"Text": "other medicines", "Type": "TREATMENT", "BeginOffset": 585, "EndOffset": 600}, {"Id": 12, "BeginOffset": 605, "EndOffset": 621, "Score": 0.4992969036102295, "Text": "multiple myeloma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9652796387672424}]}]}, "Section_2": {"Title": "2. what you need to know before you take neofordex", "Section_Content": null, "Entity_Recognition": [{"Text": "neofordex", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Id": 3, "BeginOffset": 12, "EndOffset": 21, "Score": 0.8179668188095093, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": [{"Name": "NEGATION", "Score": 0.8829777240753174}]}, {"Text": "allergic", "Type": "PROBLEM", "BeginOffset": 35, "EndOffset": 43}, {"Id": 4, "BeginOffset": 47, "EndOffset": 60, "Score": 0.9994142055511475, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 96, "EndOffset": 109}, {"Text": "a viral infection", "Type": "PROBLEM", "BeginOffset": 147, "EndOffset": 164}, {"Id": 12, "BeginOffset": 177, "EndOffset": 192, "Score": 0.969810962677002, "Text": "viral hepatitis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9004467725753784}]}, {"Id": 13, "BeginOffset": 194, "EndOffset": 200, "Score": 0.9805902242660522, "Text": "herpes", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8828034996986389}]}, {"Id": 14, "BeginOffset": 202, "EndOffset": 212, "Score": 0.9927526712417603, "Text": "chickenpox", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9170293211936951}]}, {"Id": 15, "BeginOffset": 216, "EndOffset": 224, "Score": 0.9958410859107971, "Text": "shingles", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9393619298934937}]}, {"Text": "an untreated psychiatric illness", "Type": "PROBLEM", "BeginOffset": 240, "EndOffset": 272}, {"Id": 5, "BeginOffset": 353, "EndOffset": 362, "Score": 0.5431312322616577, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "other medicinal products", "Type": "TREATMENT", "BeginOffset": 388, "EndOffset": 412}, {"Id": 50, "BeginOffset": 422, "EndOffset": 441, "Score": 0.6476773619651794, "Text": "infection treatment", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 6, "BeginOffset": 447, "EndOffset": 456, "Score": 0.6359561085700989, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "a high-dose corticosteroid)", "Type": "TREATMENT", "BeginOffset": 458, "EndOffset": 485}, {"Text": "your body's ability", "Type": "PROBLEM", "BeginOffset": 497, "EndOffset": 516}, {"Text": "fight infection", "Type": "PROBLEM", "BeginOffset": 520, "EndOffset": 535}, {"Id": 19, "BeginOffset": 558, "EndOffset": 566, "Score": 0.7011668086051941, "Text": "bacteria", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.5163636207580566}]}, {"Text": "yeasts", "Type": "PROBLEM", "BeginOffset": 568, "EndOffset": 574}, {"Id": 20, "BeginOffset": 582, "EndOffset": 591, "Score": 0.3866444528102875, "Text": "parasites", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 21, "BeginOffset": 621, "EndOffset": 631, "Score": 0.9702632427215576, "Text": "infections", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9116153717041016}]}, {"Text": "germs", "Type": "PROBLEM", "BeginOffset": 642, "EndOffset": 647}, {"Id": 22, "BeginOffset": 666, "EndOffset": 675, "Score": 0.9822371602058411, "Text": "infection", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8653706312179565}]}, {"Text": "opportunistic infections", "Type": "PROBLEM", "BeginOffset": 711, "EndOffset": 735}, {"Text": "an infection", "Type": "PROBLEM", "BeginOffset": 749, "EndOffset": 761}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 796, "EndOffset": 809}, {"Id": 25, "BeginOffset": 898, "EndOffset": 907, "Score": 0.9918612241744995, "Text": "pneumonia", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8091561794281006}]}, {"Id": 26, "BeginOffset": 909, "EndOffset": 914, "Score": 0.9970691800117493, "Text": "cough", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8025813102722168}]}, {"Id": 27, "BeginOffset": 916, "EndOffset": 921, "Score": 0.996980607509613, "Text": "fever", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8525779247283936}]}, {"Id": 28, "BeginOffset": 923, "EndOffset": 942, "Score": 0.9953538179397583, "Text": "shortness of breath", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9426577687263489}]}, {"Id": 29, "BeginOffset": 947, "EndOffset": 957, "Score": 0.971670925617218, "Text": "chest pain", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9221180081367493}]}, {"Id": 30, "BeginOffset": 977, "EndOffset": 985, "Score": 0.9834287762641907, "Text": "confused", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9314447045326233}]}, {"Id": 31, "BeginOffset": 1069, "EndOffset": 1081, "Score": 0.9800455570220947, "Text": "tuberculosis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8805413246154785}]}, {"Text": "roundworm infections", "Type": "PROBLEM", "BeginOffset": 1121, "EndOffset": 1141}, {"Id": 7, "BeginOffset": 1202, "EndOffset": 1211, "Score": 0.5693736672401428, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 33, "BeginOffset": 1264, "EndOffset": 1274, "Score": 0.9769360423088074, "Text": "chickenpox", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8915635347366333}]}, {"Id": 34, "BeginOffset": 1276, "EndOffset": 1283, "Score": 0.9907299876213074, "Text": "measles", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9129996299743652}]}, {"Id": 35, "BeginOffset": 1287, "EndOffset": 1295, "Score": 0.9962438344955444, "Text": "shingles", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8741492629051208}]}, {"Id": 36, "BeginOffset": 1413, "EndOffset": 1434, "Score": 0.6758249998092651, "Text": "psychiatric disorders", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9212399125099182}]}, {"Id": 52, "BeginOffset": 1435, "EndOffset": 1460, "Score": 0.519980788230896, "Text": "high-dose corticosteroids", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 8, "BeginOffset": 1472, "EndOffset": 1485, "Score": 0.9989727735519409, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "psychological problems", "Type": "PROBLEM", "BeginOffset": 1497, "EndOffset": 1519}, {"Id": 9, "BeginOffset": 1585, "EndOffset": 1594, "Score": 0.7292396426200867, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 56, "BeginOffset": 1657, "EndOffset": 1666, "Score": 0.9999958276748657, "Text": "currently", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_DX_NAME", "Traits": [], "Attributes": [{"Type": "DX_NAME", "Score": 0.9886412024497986, "RelationshipScore": 0.6910178065299988, "RelationshipType": "OVERLAP", "Id": 38, "BeginOffset": 1700, "EndOffset": 1713, "Text": "manic attacks", "Category": "MEDICAL_CONDITION", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8355523347854614}]}]}, {"Text": "severe depression", "Type": "PROBLEM", "BeginOffset": 1679, "EndOffset": 1696}, {"Id": 38, "BeginOffset": 1700, "EndOffset": 1713, "Score": 0.9886412024497986, "Text": "manic attacks", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8355523347854614}]}, {"Id": 39, "BeginOffset": 1756, "EndOffset": 1765, "Score": 0.9663949608802795, "Text": "depressed", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9007339477539062}]}, {"Id": 40, "BeginOffset": 1778, "EndOffset": 1800, "Score": 0.3034420311450958, "Text": "thinking about suicide", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7310439348220825}, {"Name": "DIAGNOSIS", "Score": 0.49493759870529175}]}, {"Id": 41, "BeginOffset": 1802, "EndOffset": 1810, "Score": 0.9982751607894897, "Text": "insomnia", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5618074536323547}, {"Name": "DIAGNOSIS", "Score": 0.5443082451820374}]}, {"Id": 10, "BeginOffset": 1845, "EndOffset": 1854, "Score": 0.48024487495422363, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 57, "BeginOffset": 1855, "EndOffset": 1869, "Score": 0.9999388456344604, "Text": "in the morning", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_MEDICATION_NAME", "Traits": [], "Attributes": [{"Type": "BRAND_NAME", "Score": 0.48024487495422363, "RelationshipScore": 0.9864885210990906, "RelationshipType": "OVERLAP", "Id": 10, "BeginOffset": 1845, "EndOffset": 1854, "Text": "neofordex", "Category": "MEDICATION", "Traits": []}]}, {"Id": 42, "BeginOffset": 1871, "EndOffset": 1892, "Score": 0.6258180737495422, "Text": "tumour lysis syndrome", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9391387701034546}]}, {"Text": "symptoms", "Type": "PROBLEM", "BeginOffset": 1933, "EndOffset": 1941}, {"Id": 43, "BeginOffset": 1945, "EndOffset": 1966, "Score": 0.8822101354598999, "Text": "tumour lysis syndrome", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7208680510520935}]}, {"Id": 44, "BeginOffset": 1975, "EndOffset": 1990, "Score": 0.836541473865509, "Text": "muscle cramping", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8904877305030823}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9402526617050171, "RelationshipScore": 0.566110372543335, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 1, "BeginOffset": 1975, "EndOffset": 1981, "Text": "muscle", "Category": "ANATOMY", "Traits": []}]}, {"Id": 45, "BeginOffset": 1992, "EndOffset": 2007, "Score": 0.856130063533783, "Text": "muscle weakness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9698246717453003}]}, {"Id": 46, "BeginOffset": 2009, "EndOffset": 2018, "Score": 0.9976550340652466, "Text": "confusion", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9679603576660156}]}, {"Id": 47, "BeginOffset": 2020, "EndOffset": 2031, "Score": 0.9876176714897156, "Text": "visual loss", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7421019673347473}]}, {"Id": 48, "BeginOffset": 2035, "EndOffset": 2047, "Score": 0.9761335849761963, "Text": "disturbances", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9647868871688843}]}, {"Id": 49, "BeginOffset": 2052, "EndOffset": 2071, "Score": 0.9936011433601379, "Text": "shortness of breath", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8337194919586182}]}, {"Text": "long-term treatment", "Type": "TREATMENT", "BeginOffset": 2072, "EndOffset": 2091}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 2099, "EndOffset": 2108}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 2114, "EndOffset": 2127}, {"Id": 53, "BeginOffset": 2158, "EndOffset": 2171, "Score": 0.534570038318634, "Text": "balanced diet", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "sodium retention", "Type": "TREATMENT", "BeginOffset": 2226, "EndOffset": 2242}, {"Id": 87, "BeginOffset": 2269, "EndOffset": 2281, "Score": 0.9956045150756836, "Text": "hypertension", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9746940732002258}]}, {"Id": 72, "BeginOffset": 2349, "EndOffset": 2358, "Score": 0.9482762217521667, "Text": "potassium", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 73, "BeginOffset": 2360, "EndOffset": 2367, "Score": 0.9777211546897888, "Text": "calcium", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 118, "BeginOffset": 2371, "EndOffset": 2392, "Score": 0.4403676390647888, "Text": "vitamin d supplements", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 119, "BeginOffset": 2394, "EndOffset": 2416, "Score": 0.9651690125465393, "Text": "glucocorticoid therapy", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 76, "BeginOffset": 2422, "EndOffset": 2435, "Score": 0.9996738433837891, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 2461, "EndOffset": 2470}, {"Id": 88, "BeginOffset": 2480, "EndOffset": 2488, "Score": 0.9886771440505981, "Text": "diabetes", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.96873539686203}]}, {"Id": 89, "BeginOffset": 2492, "EndOffset": 2504, "Score": 0.9993398785591125, "Text": "hypertension", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.973396897315979}]}, {"Text": "these medicines", "Type": "TREATMENT", "BeginOffset": 2518, "EndOffset": 2533}, {"Id": 90, "BeginOffset": 2603, "EndOffset": 2614, "Score": 0.9419726133346558, "Text": "blood clots", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8457292914390564}]}, {"Id": 124, "BeginOffset": 2615, "EndOffset": 2626, "Score": 0.9999974966049194, "Text": "in the past", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_DX_NAME", "Traits": [], "Attributes": [{"Type": "DX_NAME", "Score": 0.9419726133346558, "RelationshipScore": 0.9951242804527283, "RelationshipType": "OVERLAP", "Id": 90, "BeginOffset": 2603, "EndOffset": 2614, "Text": "blood clots", "Category": "MEDICAL_CONDITION", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8457292914390564}]}]}, {"Id": 77, "BeginOffset": 2671, "EndOffset": 2680, "Score": 0.7425827383995056, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 78, "BeginOffset": 2701, "EndOffset": 2714, "Score": 0.9972847700119019, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 79, "BeginOffset": 2720, "EndOffset": 2731, "Score": 0.9986441731452942, "Text": "thalidomide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 80, "BeginOffset": 2733, "EndOffset": 2745, "Score": 0.9997244477272034, "Text": "lenalidomide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 81, "BeginOffset": 2749, "EndOffset": 2761, "Score": 0.9990352392196655, "Text": "pomalidomide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 2763, "EndOffset": 2772}, {"Id": 91, "BeginOffset": 2782, "EndOffset": 2798, "Score": 0.6191885471343994, "Text": "multiple myeloma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9651554226875305}]}, {"Text": "blood clots in the veins and arteries", "Type": "PROBLEM", "BeginOffset": 2822, "EndOffset": 2859}, {"Id": 125, "BeginOffset": 2887, "EndOffset": 2898, "Score": 0.999998927116394, "Text": "immediately", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_DX_NAME", "Traits": [], "Attributes": [{"Type": "DX_NAME", "Score": 0.9955360889434814, "RelationshipScore": 0.7731556296348572, "RelationshipType": "OVERLAP", "Id": 93, "BeginOffset": 2917, "EndOffset": 2936, "Text": "shortness of breath", "Category": "MEDICAL_CONDITION", "Traits": [{"Name": "SYMPTOM", "Score": 0.9257123470306396}]}]}, {"Id": 93, "BeginOffset": 2917, "EndOffset": 2936, "Score": 0.9955360889434814, "Text": "shortness of breath", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9257123470306396}]}, {"Id": 94, "BeginOffset": 2938, "EndOffset": 2948, "Score": 0.9519702792167664, "Text": "chest pain", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8938028812408447}]}, {"Text": "swelling in the arms or legs", "Type": "PROBLEM", "BeginOffset": 2952, "EndOffset": 2980}, {"Id": 82, "BeginOffset": 3001, "EndOffset": 3014, "Score": 0.9987393021583557, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 83, "BeginOffset": 3020, "EndOffset": 3032, "Score": 0.9996373653411865, "Text": "lenalidomide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 84, "BeginOffset": 3036, "EndOffset": 3048, "Score": 0.9981651902198792, "Text": "pomalidomide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "a decrease in normal white blood cells", "Type": "PROBLEM", "BeginOffset": 3059, "EndOffset": 3097}, {"Id": 120, "BeginOffset": 3099, "EndOffset": 3110, "Score": 0.5709463357925415, "Text": "blood cells", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 96, "BeginOffset": 3127, "EndOffset": 3136, "Score": 0.9234336614608765, "Text": "infection", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8836033940315247}]}, {"Id": 121, "BeginOffset": 3145, "EndOffset": 3160, "Score": 0.7800008654594421, "Text": "blood platelets", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 97, "BeginOffset": 3181, "EndOffset": 3189, "Score": 0.9841810464859009, "Text": "bleeding", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6312563419342041}]}, {"Text": "appropriate blood tests", "Type": "TEST", "BeginOffset": 3217, "EndOffset": 3240}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 3259, "EndOffset": 3268}, {"Text": "pheochromocytoma crisis", "Type": "PROBLEM", "BeginOffset": 3270, "EndOffset": 3293}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 3294, "EndOffset": 3303}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 3309, "EndOffset": 3322}, {"Id": 98, "BeginOffset": 3333, "EndOffset": 3356, "Score": 0.8106709122657776, "Text": "pheochromocytoma crisis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9208168387413025}]}, {"Id": 99, "BeginOffset": 3378, "EndOffset": 3394, "Score": 0.896251380443573, "Text": "pheochromocytoma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9102451205253601}]}, {"Text": "a rare tumor of the adrenal glands crisis", "Type": "PROBLEM", "BeginOffset": 3398, "EndOffset": 3439}, {"Text": "the following symptoms", "Type": "PROBLEM", "BeginOffset": 3455, "EndOffset": 3477}, {"Id": 101, "BeginOffset": 3479, "EndOffset": 3488, "Score": 0.9963733553886414, "Text": "headaches", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7917044758796692}]}, {"Id": 102, "BeginOffset": 3490, "EndOffset": 3498, "Score": 0.9963787198066711, "Text": "sweating", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9118191003799438}]}, {"Id": 103, "BeginOffset": 3500, "EndOffset": 3512, "Score": 0.9971517324447632, "Text": "palpitations", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7978063225746155}]}, {"Id": 104, "BeginOffset": 3518, "EndOffset": 3530, "Score": 0.9991542100906372, "Text": "hypertension", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8129698038101196}]}, {"Text": "these signs", "Type": "PROBLEM", "BeginOffset": 3589, "EndOffset": 3600}, {"Id": 105, "BeginOffset": 3602, "EndOffset": 3615, "Score": 0.8515515327453613, "Text": "eye disorders", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8676730990409851}]}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 3616, "EndOffset": 3625}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 3631, "EndOffset": 3644}, {"Id": 106, "BeginOffset": 3655, "EndOffset": 3687, "Score": 0.6016190052032471, "Text": "central serous chorioretinopathy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8339927792549133}]}, {"Text": "an eye disease", "Type": "PROBLEM", "BeginOffset": 3689, "EndOffset": 3703}, {"Text": "blurred or distorted vision", "Type": "PROBLEM", "BeginOffset": 3718, "EndOffset": 3745}, {"Id": 66, "BeginOffset": 3782, "EndOffset": 3786, "Score": 0.9925342798233032, "Text": "eyes", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 110, "BeginOffset": 3802, "EndOffset": 3830, "Score": 0.4583567976951599, "Text": "blurring or distorted vision", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.917418897151947}]}, {"Text": "tendonitis treatment", "Type": "TREATMENT", "BeginOffset": 3888, "EndOffset": 3908}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 3914, "EndOffset": 3927}, {"Id": 112, "BeginOffset": 3938, "EndOffset": 3957, "Score": 0.8766959309577942, "Text": "tendon inflammation", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8930067420005798}]}, {"Id": 113, "BeginOffset": 3986, "EndOffset": 4004, "Score": 0.3556921184062958, "Text": "tendon may rupture", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8748388290405273}]}, {"Text": "certain antibiotics", "Type": "TREATMENT", "BeginOffset": 4047, "EndOffset": 4066}, {"Id": 114, "BeginOffset": 4074, "EndOffset": 4089, "Score": 0.8758323788642883, "Text": "kidney problems", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.48843497037887573}, {"Name": "DIAGNOSIS", "Score": 0.5260556936264038}]}, {"Id": 115, "BeginOffset": 4125, "EndOffset": 4132, "Score": 0.9717757105827332, "Text": "painful", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9205359220504761}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9891518354415894, "RelationshipScore": 0.517982006072998, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 70, "BeginOffset": 4151, "EndOffset": 4157, "Text": "joints", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9580576419830322, "RelationshipScore": 0.832984209060669, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 71, "BeginOffset": 4161, "EndOffset": 4168, "Text": "tendons", "Category": "ANATOMY", "Traits": []}]}, {"Text": "stiff or swollen joints or tendons", "Type": "PROBLEM", "BeginOffset": 4134, "EndOffset": 4168}, {"Text": "a treatment", "Type": "TREATMENT", "BeginOffset": 4232, "EndOffset": 4243}, {"Id": 127, "BeginOffset": 4265, "EndOffset": 4274, "Score": 0.9999972581863403, "Text": "currently", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_MEDICATION_NAME", "Traits": [], "Attributes": [{"Type": "GENERIC_NAME", "Score": 0.9996143579483032, "RelationshipScore": 0.519059419631958, "RelationshipType": "OVERLAP", "Id": 85, "BeginOffset": 4305, "EndOffset": 4318, "Text": "dexamethasone", "Category": "MEDICATION", "Traits": []}]}, {"Id": 128, "BeginOffset": 4290, "EndOffset": 4298, "Score": 0.9999953508377075, "Text": "recently", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_MEDICATION_NAME", "Traits": [], "Attributes": [{"Type": "GENERIC_NAME", "Score": 0.9996143579483032, "RelationshipScore": 0.691058337688446, "RelationshipType": "OVERLAP", "Id": 85, "BeginOffset": 4305, "EndOffset": 4318, "Text": "dexamethasone", "Category": "MEDICATION", "Traits": []}]}, {"Id": 85, "BeginOffset": 4305, "EndOffset": 4318, "Score": 0.9996143579483032, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 86, "BeginOffset": 4353, "EndOffset": 4362, "Score": 0.7569417357444763, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 149, "BeginOffset": 4380, "EndOffset": 4383, "Score": 0.3975200951099396, "Text": "ill", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 150, "BeginOffset": 4406, "EndOffset": 4414, "Score": 0.44246706366539, "Text": "accident", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 187, "BeginOffset": 4431, "EndOffset": 4438, "Score": 0.9118695259094238, "Text": "surgery", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "PROCEDURE_NAME", "Traits": []}, {"Text": "a vaccination (high dose of glucocorticoid", "Type": "TREATMENT", "BeginOffset": 4472, "EndOffset": 4514}, {"Text": "live virus\" vaccines", "Type": "TREATMENT", "BeginOffset": 4543, "EndOffset": 4563}, {"Id": 196, "BeginOffset": 4635, "EndOffset": 4643, "Score": 0.9999973773956299, "Text": "recently", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_MEDICATION_NAME", "Traits": [], "Attributes": [{"Type": "GENERIC_NAME", "Score": 0.3839905261993408, "RelationshipScore": 0.8274288773536682, "RelationshipType": "OVERLAP", "Id": 145, "BeginOffset": 4660, "EndOffset": 4675, "Text": "corticosteroids", "Category": "MEDICATION", "Traits": []}]}, {"Id": 191, "BeginOffset": 4650, "EndOffset": 4675, "Score": 0.8411586880683899, "Text": "high-dose corticosteroids", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "tests", "Type": "TEST", "BeginOffset": 4689, "EndOffset": 4694}, {"Id": 151, "BeginOffset": 4714, "EndOffset": 4724, "Score": 0.9764728546142578, "Text": "infections", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9477735161781311}]}, {"Text": "the tests", "Type": "TEST", "BeginOffset": 4766, "EndOffset": 4775}, {"Id": 146, "BeginOffset": 4779, "EndOffset": 4792, "Score": 0.9929459691047668, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 147, "BeginOffset": 4859, "EndOffset": 4868, "Score": 0.7234853506088257, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 152, "BeginOffset": 4883, "EndOffset": 4906, "Score": 0.6971986293792725, "Text": "liver or kidney disease", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9639647006988525}]}, {"Id": 130, "BeginOffset": 4892, "EndOffset": 4898, "Score": 0.9948810338973999, "Text": "kidney", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 153, "BeginOffset": 4922, "EndOffset": 4935, "Score": 0.97707599401474, "Text": "heart disease", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9459234476089478}]}, {"Id": 197, "BeginOffset": 4948, "EndOffset": 4956, "Score": 0.9999991655349731, "Text": "recently", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_DX_NAME", "Traits": [], "Attributes": [{"Type": "DX_NAME", "Score": 0.9746042490005493, "RelationshipScore": 0.615465521812439, "RelationshipType": "OVERLAP", "Id": 154, "BeginOffset": 4963, "EndOffset": 4975, "Text": "heart attack", "Category": "MEDICAL_CONDITION", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9514187574386597}]}]}, {"Text": "a heart attack", "Type": "PROBLEM", "BeginOffset": 4961, "EndOffset": 4975}, {"Id": 155, "BeginOffset": 4991, "EndOffset": 5010, "Score": 0.9418160915374756, "Text": "high blood pressure", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6567570567131042}]}, {"Id": 156, "BeginOffset": 5012, "EndOffset": 5028, "Score": 0.9137914180755615, "Text": "high cholesterol", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8086085915565491}]}, {"Id": 157, "BeginOffset": 5064, "EndOffset": 5072, "Score": 0.9941374063491821, "Text": "diabetes", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9261969327926636}]}, {"Id": 158, "BeginOffset": 5101, "EndOffset": 5109, "Score": 0.9923548698425293, "Text": "diabetes", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9475263357162476}]}, {"Id": 159, "BeginOffset": 5140, "EndOffset": 5152, "Score": 0.9988486766815186, "Text": "osteoporosis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.941152811050415}]}, {"Id": 160, "BeginOffset": 5209, "EndOffset": 5218, "Score": 0.9805891513824463, "Text": "menopause", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8747274279594421}]}, {"Id": 161, "BeginOffset": 5234, "EndOffset": 5242, "Score": 0.9980850219726562, "Text": "glaucoma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9262835383415222}]}, {"Text": "increased eye pressure", "Type": "PROBLEM", "BeginOffset": 5244, "EndOffset": 5266}, {"Id": 163, "BeginOffset": 5296, "EndOffset": 5304, "Score": 0.9971104860305786, "Text": "glaucoma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.954105794429779}]}, {"Id": 164, "BeginOffset": 5335, "EndOffset": 5352, "Score": 0.9611587524414062, "Text": "myasthenia gravis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.958454966545105}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9888944625854492, "RelationshipScore": 0.5771306753158569, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 134, "BeginOffset": 5378, "EndOffset": 5385, "Text": "muscles", "Category": "ANATOMY", "Traits": []}]}, {"Text": "a disease affecting the muscles", "Type": "PROBLEM", "BeginOffset": 5354, "EndOffset": 5385}, {"Text": "inflammation of a tendon (tendonitis", "Type": "PROBLEM", "BeginOffset": 5388, "EndOffset": 5424}, {"Text": "a peptic ulcer (ulcer in your stomach or duodenum", "Type": "PROBLEM", "BeginOffset": 5441, "EndOffset": 5490}, {"Id": 170, "BeginOffset": 5509, "EndOffset": 5522, "Score": 0.9845353960990906, "Text": "peptic ulcers", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9034379124641418}]}, {"Id": 171, "BeginOffset": 5524, "EndOffset": 5540, "Score": 0.9496384263038635, "Text": "stomach bleeding", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.5666451454162598}]}, {"Id": 172, "BeginOffset": 5544, "EndOffset": 5555, "Score": 0.8811662793159485, "Text": "perforation", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7983259558677673}]}, {"Text": "inflammation of the colon", "Type": "PROBLEM", "BeginOffset": 5571, "EndOffset": 5596}, {"Id": 174, "BeginOffset": 5598, "EndOffset": 5612, "Score": 0.9720101356506348, "Text": "diverticulitis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9369619488716125}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9961263537406921, "RelationshipScore": 0.7644016146659851, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 139, "BeginOffset": 5591, "EndOffset": 5596, "Text": "colon", "Category": "ANATOMY", "Traits": []}]}, {"Id": 198, "BeginOffset": 5622, "EndOffset": 5630, "Score": 0.9999979734420776, "Text": "recently", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_PROCEDURE_NAME", "Traits": [], "Attributes": [{"Type": "PROCEDURE_NAME", "Score": 0.9387694597244263, "RelationshipScore": 0.5596998929977417, "RelationshipType": "OVERLAP", "Id": 192, "BeginOffset": 5635, "EndOffset": 5642, "Text": "surgery", "Category": "TEST_TREATMENT_PROCEDURE", "Traits": []}]}, {"Id": 192, "BeginOffset": 5635, "EndOffset": 5642, "Score": 0.9387694597244263, "Text": "surgery", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "PROCEDURE_NAME", "Traits": []}, {"Id": 140, "BeginOffset": 5650, "EndOffset": 5659, "Score": 0.7677314877510071, "Text": "intestine", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 175, "BeginOffset": 5702, "EndOffset": 5718, "Score": 0.9806550741195679, "Text": "pheochromocytoma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9331940412521362}]}, {"Text": "a tumor of the adrenal glands", "Type": "PROBLEM", "BeginOffset": 5720, "EndOffset": 5749}, {"Text": "the listed diseases", "Type": "PROBLEM", "BeginOffset": 5812, "EndOffset": 5831}, {"Id": 177, "BeginOffset": 5873, "EndOffset": 5885, "Score": 0.762509822845459, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.41743969917297363}]}, {"Id": 148, "BeginOffset": 5889, "EndOffset": 5898, "Score": 0.2099435180425644, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "thinning of the bones (osteoporosis", "Type": "PROBLEM", "BeginOffset": 5931, "EndOffset": 5966}, {"Id": 180, "BeginOffset": 5969, "EndOffset": 5988, "Score": 0.9255178570747375, "Text": "high blood pressure", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8067744374275208}]}, {"Id": 181, "BeginOffset": 5990, "EndOffset": 6010, "Score": 0.7592671513557434, "Text": "low potassium levels", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7744271159172058}]}, {"Id": 182, "BeginOffset": 6012, "EndOffset": 6020, "Score": 0.9866683483123779, "Text": "diabetes", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9334684014320374}]}, {"Id": 183, "BeginOffset": 6022, "EndOffset": 6049, "Score": 0.4165915548801422, "Text": "susceptibility to infection", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8277410268783569}]}, {"Text": "thinning of the skin", "Type": "PROBLEM", "BeginOffset": 6054, "EndOffset": 6074}, {"Id": 185, "BeginOffset": 6168, "EndOffset": 6184, "Score": 0.6987977623939514, "Text": "multiple myeloma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9576297998428345}]}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 6186, "EndOffset": 6199}, {"Id": 186, "BeginOffset": 6262, "EndOffset": 6264, "Score": 0.9979448914527893, "Text": "18", "Category": "PROTECTED_HEALTH_INFORMATION", "Type": "AGE", "Traits": []}, {"Text": "other medicines", "Type": "TREATMENT", "BeginOffset": 6273, "EndOffset": 6288}, {"Text": "any other medicines", "Type": "TREATMENT", "BeginOffset": 6387, "EndOffset": 6406}, {"Text": "all medicines", "Type": "TREATMENT", "BeginOffset": 6446, "EndOffset": 6459}, {"Id": 203, "BeginOffset": 6492, "EndOffset": 6501, "Score": 0.7981469035148621, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "these medicines", "Type": "TREATMENT", "BeginOffset": 6529, "EndOffset": 6544}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 6561, "EndOffset": 6570}, {"Id": 204, "BeginOffset": 6576, "EndOffset": 6585, "Score": 0.7513843178749084, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 205, "BeginOffset": 6592, "EndOffset": 6603, "Score": 0.9974740147590637, "Text": "thalidomide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 206, "BeginOffset": 6605, "EndOffset": 6617, "Score": 0.9996529817581177, "Text": "lenalidomide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 207, "BeginOffset": 6621, "EndOffset": 6633, "Score": 0.9984083771705627, "Text": "pomalidomide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 238, "BeginOffset": 6667, "EndOffset": 6684, "Score": 0.5023683309555054, "Text": "pregnancy testing", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TEST_NAME", "Traits": []}, {"Text": "prevention requirements", "Type": "TREATMENT", "BeginOffset": 6689, "EndOffset": 6712}, {"Text": "the following medicines", "Type": "TREATMENT", "BeginOffset": 6749, "EndOffset": 6772}, {"Id": 208, "BeginOffset": 6819, "EndOffset": 6828, "Score": 0.7128958702087402, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 209, "BeginOffset": 6877, "EndOffset": 6897, "Score": 0.9816426038742065, "Text": "acetylsalicylic acid", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "many medicines", "Type": "TREATMENT", "BeginOffset": 6922, "EndOffset": 6936}, {"Id": 221, "BeginOffset": 6953, "EndOffset": 6957, "Score": 0.9876218438148499, "Text": "pain", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8530187010765076}]}, {"Text": "lower fever", "Type": "PROBLEM", "BeginOffset": 6962, "EndOffset": 6973}, {"Id": 223, "BeginOffset": 7000, "EndOffset": 7008, "Score": 0.9902101755142212, "Text": "bleeding", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6658766865730286}]}, {"Text": "a vaccination", "Type": "TREATMENT", "BeginOffset": 7076, "EndOffset": 7089}, {"Id": 240, "BeginOffset": 7112, "EndOffset": 7122, "Score": 0.3714779019355774, "Text": "vaccinated", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "precautions", "Type": "TREATMENT", "BeginOffset": 7207, "EndOffset": 7218}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 7221, "EndOffset": 7230}, {"Id": 241, "BeginOffset": 7243, "EndOffset": 7265, "Score": 0.4545535743236542, "Text": "blood potassium levels", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TEST_NAME", "Traits": []}, {"Text": "some diuretics", "Type": "TREATMENT", "BeginOffset": 7280, "EndOffset": 7294}, {"Id": 243, "BeginOffset": 7298, "EndOffset": 7307, "Score": 0.9339795112609863, "Text": "laxatives", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 244, "BeginOffset": 7309, "EndOffset": 7333, "Score": 0.6718303561210632, "Text": "amphotericin b injection", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 211, "BeginOffset": 7335, "EndOffset": 7349, "Score": 0.9898777604103088, "Text": "tetracosactide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 224, "BeginOffset": 7370, "EndOffset": 7396, "Score": 0.5548074245452881, "Text": "decreased potassium levels", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Text": "potassium", "Type": "TREATMENT", "BeginOffset": 7443, "EndOffset": 7452}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 7456, "EndOffset": 7465}, {"Id": 225, "BeginOffset": 7496, "EndOffset": 7517, "Score": 0.8135064840316772, "Text": "abnormal heart rhythm", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6582165956497192}]}, {"Id": 199, "BeginOffset": 7505, "EndOffset": 7510, "Score": 0.7056747078895569, "Text": "heart", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "some medicines", "Type": "TREATMENT", "BeginOffset": 7524, "EndOffset": 7538}, {"Id": 226, "BeginOffset": 7556, "EndOffset": 7569, "Score": 0.959815502166748, "Text": "heart disease", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9561770558357239}]}, {"Id": 212, "BeginOffset": 7574, "EndOffset": 7583, "Score": 0.5551528930664062, "Text": "digitalis", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "low levels of potassium", "Type": "PROBLEM", "BeginOffset": 7592, "EndOffset": 7615}, {"Id": 227, "BeginOffset": 7637, "EndOffset": 7657, "Score": 0.8116386532783508, "Text": "abnormal heart beats", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.850389301776886}]}, {"Id": 201, "BeginOffset": 7646, "EndOffset": 7651, "Score": 0.8442788124084473, "Text": "heart", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 7661, "EndOffset": 7670}, {"Id": 228, "BeginOffset": 7680, "EndOffset": 7692, "Score": 0.9972719550132751, "Text": "hypertension", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9743591547012329}]}, {"Id": 251, "BeginOffset": 7772, "EndOffset": 7799, "Score": 0.9778878092765808, "Text": "anti-hypertensive treatment", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 7803, "EndOffset": 7812}, {"Id": 229, "BeginOffset": 7822, "EndOffset": 7829, "Score": 0.8633492588996887, "Text": "anaemia", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9228112697601318}]}, {"Text": "erythropoietin (epo)", "Type": "TREATMENT", "BeginOffset": 7838, "EndOffset": 7858}, {"Text": "other medicines", "Type": "TREATMENT", "BeginOffset": 7862, "EndOffset": 7877}, {"Id": 254, "BeginOffset": 7886, "EndOffset": 7913, "Score": 0.9982653260231018, "Text": "hormone replacement therapy", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 230, "BeginOffset": 7953, "EndOffset": 7964, "Score": 0.9789149165153503, "Text": "blood clots", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9389358758926392}]}, {"Text": "side effects\"", "Type": "PROBLEM", "BeginOffset": 8027, "EndOffset": 8040}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 8045, "EndOffset": 8054}, {"Id": 232, "BeginOffset": 8064, "EndOffset": 8068, "Score": 0.9925298094749451, "Text": "pain", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8743797540664673}]}, {"Id": 233, "BeginOffset": 8070, "EndOffset": 8082, "Score": 0.9937095642089844, "Text": "inflammation", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8182949423789978}]}, {"Id": 234, "BeginOffset": 8087, "EndOffset": 8092, "Score": 0.9904116988182068, "Text": "fever", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6335113048553467}]}, {"Id": 255, "BeginOffset": 8094, "EndOffset": 8131, "Score": 0.3633045256137848, "Text": "non-steroidal anti-inflammatory drugs", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 215, "BeginOffset": 8138, "EndOffset": 8147, "Score": 0.9956738352775574, "Text": "ibuprofen", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 216, "BeginOffset": 8149, "EndOffset": 8157, "Score": 0.9988824725151062, "Text": "naproxen", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 217, "BeginOffset": 8159, "EndOffset": 8169, "Score": 0.99899822473526, "Text": "diclofenac", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 218, "BeginOffset": 8171, "EndOffset": 8180, "Score": 0.9988623857498169, "Text": "meloxicam", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "others", "Type": "TREATMENT", "BeginOffset": 8185, "EndOffset": 8191}, {"Id": 235, "BeginOffset": 8217, "EndOffset": 8225, "Score": 0.9788113236427307, "Text": "bleeding", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.746919572353363}]}, {"Text": "open sores in the stomach", "Type": "PROBLEM", "BeginOffset": 8229, "EndOffset": 8254}, {"Text": "27", "Type": "NUMBER", "BeginOffset": 8256, "EndOffset": 8258}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 8261, "EndOffset": 8270}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 8275, "EndOffset": 8284}, {"Id": 237, "BeginOffset": 8288, "EndOffset": 8296, "Score": 0.980028510093689, "Text": "diabetes", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9507923722267151}]}, {"Id": 219, "BeginOffset": 8301, "EndOffset": 8310, "Score": 0.40649884939193726, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 256, "BeginOffset": 8322, "EndOffset": 8335, "Score": 0.42541345953941345, "Text": "glucose level", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TEST_NAME", "Traits": []}, {"Id": 257, "BeginOffset": 8370, "EndOffset": 8390, "Score": 0.9774799942970276, "Text": "blood glucose levels", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TEST_NAME", "Traits": []}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 8428, "EndOffset": 8437}, {"Id": 264, "BeginOffset": 8482, "EndOffset": 8505, "Score": 0.44818955659866333, "Text": "anti-diabetic medicines", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "some antibiotics", "Type": "TREATMENT", "BeginOffset": 8509, "EndOffset": 8525}, {"Id": 266, "BeginOffset": 8535, "EndOffset": 8551, "Score": 0.9826707243919373, "Text": "fluoroquinolones", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 297, "BeginOffset": 8578, "EndOffset": 8588, "Score": 0.9959942102432251, "Text": "tendonitis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9675753116607666}]}, {"Text": "rupture of the affected tendon", "Type": "PROBLEM", "BeginOffset": 8616, "EndOffset": 8646}, {"Text": "long-term treatment", "Type": "TREATMENT", "BeginOffset": 8667, "EndOffset": 8686}, {"Text": "certain medicines", "Type": "TREATMENT", "BeginOffset": 8690, "EndOffset": 8707}, {"Id": 299, "BeginOffset": 8717, "EndOffset": 8723, "Score": 0.978574275970459, "Text": "cancer", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9778680801391602}]}, {"Id": 267, "BeginOffset": 8733, "EndOffset": 8745, "Score": 0.9946624636650085, "Text": "methotrexate", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 300, "BeginOffset": 8772, "EndOffset": 8781, "Score": 0.9970867037773132, "Text": "infection", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.89009028673172}]}, {"Id": 301, "BeginOffset": 8783, "EndOffset": 8791, "Score": 0.9949967861175537, "Text": "bleeding", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 302, "BeginOffset": 8795, "EndOffset": 8802, "Score": 0.9944530129432678, "Text": "anaemia", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7866111993789673}]}, {"Text": "the following medicines", "Type": "TREATMENT", "BeginOffset": 8804, "EndOffset": 8827}, {"Text": "neofordex these medicines", "Type": "TREATMENT", "BeginOffset": 8856, "EndOffset": 8881}, {"Id": 269, "BeginOffset": 8907, "EndOffset": 8916, "Score": 0.6123958826065063, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "aminogluthetimide (medicine", "Type": "TREATMENT", "BeginOffset": 8920, "EndOffset": 8947}, {"Id": 303, "BeginOffset": 8957, "EndOffset": 8975, "Score": 0.9008327722549438, "Text": "cushing's syndrome", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.973000705242157}]}, {"Id": 304, "BeginOffset": 8979, "EndOffset": 8992, "Score": 0.9688525199890137, "Text": "breast cancer", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9816443920135498}]}, {"Id": 271, "BeginOffset": 8997, "EndOffset": 9012, "Score": 0.3733590841293335, "Text": "anticonvulsants", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 305, "BeginOffset": 9035, "EndOffset": 9043, "Score": 0.9665192365646362, "Text": "epilepsy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9614846110343933}]}, {"Id": 272, "BeginOffset": 9053, "EndOffset": 9066, "Score": 0.9995625615119934, "Text": "carbamazepine", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 273, "BeginOffset": 9068, "EndOffset": 9080, "Score": 0.9946000576019287, "Text": "fosphenytoin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 274, "BeginOffset": 9082, "EndOffset": 9095, "Score": 0.9986950755119324, "Text": "phenobarbital", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 275, "BeginOffset": 9097, "EndOffset": 9106, "Score": 0.9985101819038391, "Text": "phenytoin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 276, "BeginOffset": 9108, "EndOffset": 9117, "Score": 0.9989575147628784, "Text": "primidone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 277, "BeginOffset": 9121, "EndOffset": 9131, "Score": 0.993026852607727, "Text": "rifampicin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 306, "BeginOffset": 9147, "EndOffset": 9159, "Score": 0.9539913535118103, "Text": "tuberculosis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9695960879325867}]}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 9164, "EndOffset": 9173}, {"Text": "an upset stomach", "Type": "PROBLEM", "BeginOffset": 9178, "EndOffset": 9194}, {"Text": "example antacids", "Type": "TREATMENT", "BeginOffset": 9200, "EndOffset": 9216}, {"Id": 279, "BeginOffset": 9229, "EndOffset": 9242, "Score": 0.9647468328475952, "Text": "colestyramine", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "such medicines", "Type": "TREATMENT", "BeginOffset": 9289, "EndOffset": 9303}, {"Id": 280, "BeginOffset": 9309, "EndOffset": 9318, "Score": 0.7394048571586609, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 281, "BeginOffset": 9364, "EndOffset": 9373, "Score": 0.8070998787879944, "Text": "ephedrine", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 308, "BeginOffset": 9384, "EndOffset": 9398, "Score": 0.6954266428947449, "Text": "asthma attacks", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9434329867362976}]}, {"Id": 309, "BeginOffset": 9410, "EndOffset": 9426, "Score": 0.945279061794281, "Text": "nasal congestion", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9012927412986755}]}, {"Text": "these medicines", "Type": "TREATMENT", "BeginOffset": 9429, "EndOffset": 9444}, {"Id": 282, "BeginOffset": 9472, "EndOffset": 9481, "Score": 0.8160303831100464, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 283, "BeginOffset": 9485, "EndOffset": 9495, "Score": 0.9944701194763184, "Text": "aprepitant", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 284, "BeginOffset": 9499, "EndOffset": 9512, "Score": 0.9954380393028259, "Text": "fosaprepitant", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 310, "BeginOffset": 9535, "EndOffset": 9541, "Score": 0.9926446676254272, "Text": "nausea", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8278795480728149}]}, {"Id": 311, "BeginOffset": 9546, "EndOffset": 9554, "Score": 0.996052086353302, "Text": "vomiting", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8669248223304749}]}, {"Id": 326, "BeginOffset": 9561, "EndOffset": 9568, "Score": 0.6643400192260742, "Text": "surgery", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "PROCEDURE_NAME", "Traits": []}, {"Text": "chemotherapy [cancer treatment", "Type": "TREATMENT", "BeginOffset": 9582, "EndOffset": 9612}, {"Id": 285, "BeginOffset": 9618, "EndOffset": 9629, "Score": 0.5437248945236206, "Text": "antibiotics", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "active substance names", "Type": "TREATMENT", "BeginOffset": 9636, "EndOffset": 9658}, {"Id": 286, "BeginOffset": 9669, "EndOffset": 9674, "Score": 0.4610600769519806, "Text": "mycin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 287, "BeginOffset": 9679, "EndOffset": 9690, "Score": 0.636993944644928, "Text": "antifungals", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 313, "BeginOffset": 9701, "EndOffset": 9718, "Score": 0.9360259175300598, "Text": "fungal infections", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9694026708602905}]}, {"Id": 288, "BeginOffset": 9758, "EndOffset": 9766, "Score": 0.9904898405075073, "Text": "conazole", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 289, "BeginOffset": 9772, "EndOffset": 9790, "Score": 0.6912211775779724, "Text": "anti-hiv medicines", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 290, "BeginOffset": 9836, "EndOffset": 9845, "Score": 0.5365797281265259, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "these medicines", "Type": "TREATMENT", "BeginOffset": 9874, "EndOffset": 9889}, {"Id": 332, "BeginOffset": 9906, "EndOffset": 9925, "Score": 0.943170428276062, "Text": "oral contraceptives", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 333, "BeginOffset": 9930, "EndOffset": 9957, "Score": 0.9986764788627625, "Text": "hormone replacement therapy", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 334, "BeginOffset": 9959, "EndOffset": 9962, "Score": 0.37797781825065613, "Text": "hrt", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "effective measures", "Type": "TREATMENT", "BeginOffset": 9980, "EndOffset": 9998}, {"Id": 314, "BeginOffset": 10008, "EndOffset": 10017, "Score": 0.9239941239356995, "Text": "pregnancy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9349420070648193}]}, {"Id": 315, "BeginOffset": 10046, "EndOffset": 10055, "Score": 0.9795929193496704, "Text": "pregnancy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9294359087944031}]}, {"Id": 316, "BeginOffset": 10076, "EndOffset": 10085, "Score": 0.3583523631095886, "Text": "fertility", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 335, "BeginOffset": 10105, "EndOffset": 10124, "Score": 0.9225084185600281, "Text": "oral anticoagulants", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "increased bleeding risk", "Type": "PROBLEM", "BeginOffset": 10154, "EndOffset": 10177}, {"Text": "your blood coagulation parameters", "Type": "TEST", "BeginOffset": 10219, "EndOffset": 10252}, {"Text": "certain medicines", "Type": "TREATMENT", "BeginOffset": 10270, "EndOffset": 10287}, {"Id": 318, "BeginOffset": 10297, "EndOffset": 10303, "Score": 0.9770570993423462, "Text": "cancer", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9765172004699707}]}, {"Id": 293, "BeginOffset": 10313, "EndOffset": 10322, "Score": 0.9997718930244446, "Text": "docetaxel", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 294, "BeginOffset": 10327, "EndOffset": 10343, "Score": 0.9998458623886108, "Text": "cyclophosphamide", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 319, "BeginOffset": 10367, "EndOffset": 10380, "Score": 0.35455504059791565, "Text": "liver effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7427119612693787}]}, {"Id": 295, "BeginOffset": 10384, "EndOffset": 10393, "Score": 0.9960781931877136, "Text": "lapatinib", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 320, "BeginOffset": 10409, "EndOffset": 10415, "Score": 0.9830458164215088, "Text": "cancer", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9745258092880249}]}, {"Id": 296, "BeginOffset": 10451, "EndOffset": 10462, "Score": 0.9962319731712341, "Text": "ciclosporin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "a medicine", "Type": "TREATMENT", "BeginOffset": 10464, "EndOffset": 10474}, {"Id": 321, "BeginOffset": 10492, "EndOffset": 10508, "Score": 0.7522545456886292, "Text": "immune reactions", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6879981756210327}]}, {"Id": 322, "BeginOffset": 10539, "EndOffset": 10550, "Score": 0.4608994424343109, "Text": "convulsions", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 337, "BeginOffset": 10593, "EndOffset": 10606, "Score": 0.9996570348739624, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 338, "BeginOffset": 10611, "EndOffset": 10622, "Score": 0.9975220561027527, "Text": "ciclosporin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 339, "BeginOffset": 10643, "EndOffset": 10652, "Score": 0.8334195017814636, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 340, "BeginOffset": 10657, "EndOffset": 10669, "Score": 0.9980903267860413, "Text": "ciclosporine", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 341, "BeginOffset": 10705, "EndOffset": 10714, "Score": 0.9994238615036011, "Text": "midazolam", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 379, "BeginOffset": 10724, "EndOffset": 10737, "Score": 0.6895187497138977, "Text": "sleeping pill", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 357, "BeginOffset": 10763, "EndOffset": 10771, "Score": 0.9770925045013428, "Text": "epilepsy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9629601836204529}]}, {"Id": 342, "BeginOffset": 10805, "EndOffset": 10815, "Score": 0.7768353223800659, "Text": "ivermectin", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "certain worm infections", "Type": "PROBLEM", "BeginOffset": 10821, "EndOffset": 10844}, {"Id": 343, "BeginOffset": 10891, "EndOffset": 10901, "Score": 0.7365800142288208, "Text": "ivermectin", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "neofordex administration", "Type": "TREATMENT", "BeginOffset": 10941, "EndOffset": 10965}, {"Id": 345, "BeginOffset": 11024, "EndOffset": 11033, "Score": 0.9979658126831055, "Text": "rifabutin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 346, "BeginOffset": 11037, "EndOffset": 11046, "Score": 0.9985342025756836, "Text": "isoniazid", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 359, "BeginOffset": 11062, "EndOffset": 11074, "Score": 0.9629994034767151, "Text": "tuberculosis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9554831385612488}]}, {"Id": 347, "BeginOffset": 11108, "EndOffset": 11117, "Score": 0.8876782059669495, "Text": "indinavir", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 360, "BeginOffset": 11144, "EndOffset": 11147, "Score": 0.9002590775489807, "Text": "hiv", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8371615409851074}]}, {"Id": 348, "BeginOffset": 11181, "EndOffset": 11193, "Score": 0.9993109703063965, "Text": "erythromycin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 349, "BeginOffset": 11226, "EndOffset": 11238, "Score": 0.7809255719184875, "Text": "praziquantel", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "certain worm infections", "Type": "PROBLEM", "BeginOffset": 11244, "EndOffset": 11267}, {"Id": 362, "BeginOffset": 11299, "EndOffset": 11306, "Score": 0.6318615674972534, "Text": "failure", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6864759922027588}]}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 11310, "EndOffset": 11319}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 11331, "EndOffset": 11340}, {"Id": 350, "BeginOffset": 11346, "EndOffset": 11358, "Score": 0.7902982234954834, "Text": "praziquantel", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 351, "BeginOffset": 11363, "EndOffset": 11372, "Score": 0.7134373784065247, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 363, "BeginOffset": 11415, "EndOffset": 11424, "Score": 0.9743608832359314, "Text": "pregnancy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9436551332473755}]}, {"Id": 364, "BeginOffset": 11466, "EndOffset": 11474, "Score": 0.992226243019104, "Text": "pregnant", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9480711817741394}]}, {"Id": 365, "BeginOffset": 11515, "EndOffset": 11523, "Score": 0.9945613741874695, "Text": "pregnant", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9551403522491455}]}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 11611, "EndOffset": 11624}, {"Id": 366, "BeginOffset": 11649, "EndOffset": 11657, "Score": 0.9940593242645264, "Text": "pregnant", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.950646162033081}]}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 11665, "EndOffset": 11674}, {"Id": 352, "BeginOffset": 11680, "EndOffset": 11689, "Score": 0.5375572443008423, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 367, "BeginOffset": 11706, "EndOffset": 11730, "Score": 0.980087399482727, "Text": "congenital malformations", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.970280110836029}]}, {"Text": "appropriate contraception", "Type": "TREATMENT", "BeginOffset": 11762, "EndOffset": 11787}, {"Id": 353, "BeginOffset": 11808, "EndOffset": 11817, "Score": 0.6223152279853821, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": [{"Name": "NEGATION", "Score": 0.43305546045303345}]}, {"Id": 368, "BeginOffset": 11825, "EndOffset": 11834, "Score": 0.9372434020042419, "Text": "pregnancy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9310151934623718}]}, {"Text": "your clinical condition", "Type": "PROBLEM", "BeginOffset": 11842, "EndOffset": 11865}, {"Id": 354, "BeginOffset": 11890, "EndOffset": 11903, "Score": 0.9990806579589844, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 369, "BeginOffset": 11947, "EndOffset": 11955, "Score": 0.9961103796958923, "Text": "pregnant", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9488236904144287}]}, {"Id": 370, "BeginOffset": 11973, "EndOffset": 11981, "Score": 0.9973004460334778, "Text": "pregnant", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9385676383972168}]}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 11989, "EndOffset": 11998}, {"Text": "glucocorticoids", "Type": "TREATMENT", "BeginOffset": 12000, "EndOffset": 12015}, {"Id": 355, "BeginOffset": 12263, "EndOffset": 12272, "Score": 0.6806548237800598, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "breast-feeding", "Type": "TREATMENT", "BeginOffset": 12301, "EndOffset": 12315}, {"Id": 356, "BeginOffset": 12347, "EndOffset": 12356, "Score": 0.40536215901374817, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "machines neofordex", "Type": "TREATMENT", "BeginOffset": 12390, "EndOffset": 12408}, {"Id": 371, "BeginOffset": 12565, "EndOffset": 12577, "Score": 0.9612416625022888, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.880955696105957}]}, {"Id": 372, "BeginOffset": 12587, "EndOffset": 12596, "Score": 0.9985522627830505, "Text": "confusion", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9702910780906677}]}, {"Id": 373, "BeginOffset": 12598, "EndOffset": 12612, "Score": 0.9995089769363403, "Text": "hallucinations", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9860754609107971}]}, {"Id": 374, "BeginOffset": 12614, "EndOffset": 12623, "Score": 0.9998321533203125, "Text": "dizziness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9921437501907349}]}, {"Id": 375, "BeginOffset": 12625, "EndOffset": 12634, "Score": 0.9985456466674805, "Text": "tiredness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.986305832862854}]}, {"Id": 376, "BeginOffset": 12636, "EndOffset": 12646, "Score": 0.9903333783149719, "Text": "sleepiness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9839134812355042}]}, {"Id": 377, "BeginOffset": 12648, "EndOffset": 12656, "Score": 0.9686296582221985, "Text": "fainting", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9686651229858398}]}, {"Id": 378, "BeginOffset": 12660, "EndOffset": 12674, "Score": 0.875032365322113, "Text": "blurred vision", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9286288619041443}]}, {"Text": "lactose neofordex", "Type": "TREATMENT", "BeginOffset": 12695, "EndOffset": 12712}, {"Text": "lactose", "Type": "TREATMENT", "BeginOffset": 12722, "EndOffset": 12729}, {"Id": 383, "BeginOffset": 12791, "EndOffset": 12817, "Score": 0.4528633654117584, "Text": "intolerance to some sugars", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5469043254852295}]}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 12853, "EndOffset": 12866}]}, "Section_3": {"Title": "3. how to take neofordex", "Section_Content": "always take this medicine exactly as your doctor has told you. check with your doctor if you are not sure. your doctor will decide the dose and how often you should take neofordex. this can vary according to your condition and to other associated treatment(s). the recommended dose is one tablet each time. if you are over 65 years old and/or frail, your doctor may prescribe a half tablet each time. do not exceed or take less than the prescribed dose. you must take this medicine on the appropriate days, exactly as your doctor prescribed. your doctor may change the dose and frequency of administration based on certain parameters including your blood analyses, your general condition, other medicines prescribed to you and your response to the treatment. swallow the prescribed dose of one tablet (40 mg) or half a tablet (20 mg) in the morning with a glass of water. if your dose is half a tablet (20 mg), the tablet should be divided into two equal halves using the score line. take one half tablet straightaway. do not save the spare half tablet to take on another day as this medicine may deteriorate once divided and taken out of its packaging. then, keep the spare half tablet in a safe place, out of the sight and reach of children, until you can throw it away properly, as you should not throw away any medicines in wastewater or household waste. ask your pharmacist how to throw them away. if you have difficulties taking the tablet out of the blister or breaking the tablet, ask somebody for help. insomnia may be minimised by administering neofordex in the morning. if you take more neofordex than you should if you take too much neofordex contact your doctor or hospital immediately. if you forget to take neofordex if you forget to take neofordex at the usual time and if you are less than 12 hours late: take the tablet immediately. if you are more than 12 hours late: do not take the tablet but take the next tablet at the usual time. do not take a double dose to make up for a forgotten tablet. if you stop taking neofordex you may experience serious side effects if you stop taking this medicine suddenly. if you stop taking this medicine too quickly, you may have low blood pressure. you may also feel a 'withdrawal symptom'. this may include headache, problems with your vision (including pain or swelling in the eye), feeling or being sick, fever, pain in your muscles and joints, swelling in the inside of your nose, weight loss, itchy skin and conjunctivitis. if your treatment is to be stopped follow your doctor's advice. if you have any further questions on the use of this medicine, ask your doctor or pharmacist.", "Entity_Recognition": [{"Text": "neofordex", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 12, "EndOffset": 25}, {"Id": 0, "BeginOffset": 170, "EndOffset": 179, "Score": 0.7992884516716003, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": [], "Attributes": [{"Type": "DOSAGE", "Score": 0.49990740418434143, "RelationshipScore": 0.5851108431816101, "RelationshipType": "DOSAGE", "Id": 1, "BeginOffset": 285, "EndOffset": 295, "Text": "one tablet", "Category": "MEDICATION", "Traits": []}]}, {"Text": "65", "Type": "NUMBER", "BeginOffset": 323, "EndOffset": 325}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 468, "EndOffset": 481}, {"Text": "administration", "Type": "TREATMENT", "BeginOffset": 591, "EndOffset": 605}, {"Text": "your blood analyses", "Type": "TEST", "BeginOffset": 644, "EndOffset": 663}, {"Text": "your general condition", "Type": "PROBLEM", "BeginOffset": 665, "EndOffset": 687}, {"Text": "other medicines", "Type": "TREATMENT", "BeginOffset": 689, "EndOffset": 704}, {"Text": "the treatment", "Type": "TREATMENT", "BeginOffset": 744, "EndOffset": 757}, {"Text": "swallow", "Type": "TREATMENT", "BeginOffset": 759, "EndOffset": 766}, {"Text": "the score line", "Type": "TREATMENT", "BeginOffset": 968, "EndOffset": 982}, {"Text": "its packaging", "Type": "TREATMENT", "BeginOffset": 1139, "EndOffset": 1152}, {"Text": "the blister", "Type": "PROBLEM", "BeginOffset": 1453, "EndOffset": 1464}, {"Id": 16, "BeginOffset": 1512, "EndOffset": 1520, "Score": 0.9975621700286865, "Text": "insomnia", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8823602795600891}]}, {"Id": 11, "BeginOffset": 1555, "EndOffset": 1564, "Score": 0.811083197593689, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 20, "BeginOffset": 1565, "EndOffset": 1579, "Score": 0.9999926090240479, "Text": "in the morning", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_MEDICATION_NAME", "Traits": [], "Attributes": [{"Type": "BRAND_NAME", "Score": 0.811083197593689, "RelationshipScore": 0.9864885210990906, "RelationshipType": "OVERLAP", "Id": 11, "BeginOffset": 1555, "EndOffset": 1564, "Text": "neofordex", "Category": "MEDICATION", "Traits": []}]}, {"Id": 12, "BeginOffset": 1598, "EndOffset": 1607, "Score": 0.6717079877853394, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 13, "BeginOffset": 1722, "EndOffset": 1731, "Score": 0.8938088417053223, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Id": 14, "BeginOffset": 1754, "EndOffset": 1763, "Score": 0.9224727153778076, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": []}, {"Text": "12", "Type": "NUMBER", "BeginOffset": 1807, "EndOffset": 1809}, {"Text": "12", "Type": "NUMBER", "BeginOffset": 1872, "EndOffset": 1874}, {"Text": "a double dose", "Type": "TREATMENT", "BeginOffset": 1966, "EndOffset": 1979}, {"Id": 30, "BeginOffset": 2034, "EndOffset": 2043, "Score": 0.8882730007171631, "Text": "neofordex", "Category": "MEDICATION", "Type": "BRAND_NAME", "Traits": [{"Name": "NEGATION", "Score": 0.7420775890350342}]}, {"Text": "serious side effects", "Type": "PROBLEM", "BeginOffset": 2063, "EndOffset": 2083}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 2103, "EndOffset": 2116}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 2146, "EndOffset": 2159}, {"Id": 32, "BeginOffset": 2186, "EndOffset": 2204, "Score": 0.7313764691352844, "Text": "low blood pressure", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.728122889995575}]}, {"Text": "a 'withdrawal symptom", "Type": "PROBLEM", "BeginOffset": 2224, "EndOffset": 2245}, {"Id": 34, "BeginOffset": 2265, "EndOffset": 2273, "Score": 0.9959709048271179, "Text": "headache", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9070523381233215}]}, {"Id": 35, "BeginOffset": 2275, "EndOffset": 2300, "Score": 0.6363611221313477, "Text": "problems with your vision", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9145246148109436}]}, {"Id": 36, "BeginOffset": 2312, "EndOffset": 2316, "Score": 0.9935334920883179, "Text": "pain", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9515351057052612}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9939470291137695, "RelationshipScore": 0.993022620677948, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 24, "BeginOffset": 2336, "EndOffset": 2339, "Text": "eye", "Category": "ANATOMY", "Traits": []}]}, {"Text": "swelling in the eye", "Type": "PROBLEM", "BeginOffset": 2320, "EndOffset": 2339}, {"Id": 38, "BeginOffset": 2342, "EndOffset": 2363, "Score": 0.4084559381008148, "Text": "feeling or being sick", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9500852823257446}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9939470291137695, "RelationshipScore": 0.8100181818008423, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 24, "BeginOffset": 2336, "EndOffset": 2339, "Text": "eye", "Category": "ANATOMY", "Traits": []}]}, {"Id": 39, "BeginOffset": 2365, "EndOffset": 2370, "Score": 0.9968464970588684, "Text": "fever", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9704385995864868}]}, {"Text": "pain in your muscles and joints", "Type": "PROBLEM", "BeginOffset": 2372, "EndOffset": 2403}, {"Id": 41, "BeginOffset": 2405, "EndOffset": 2413, "Score": 0.975872278213501, "Text": "swelling", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9566211700439453}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9508626461029053, "RelationshipScore": 0.9986230134963989, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 25, "BeginOffset": 2385, "EndOffset": 2392, "Text": "muscles", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9968486428260803, "RelationshipScore": 0.9820488095283508, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 26, "BeginOffset": 2397, "EndOffset": 2403, "Text": "joints", "Category": "ANATOMY", "Traits": []}, {"Type": "DIRECTION", "Score": 0.8258499503135681, "RelationshipScore": 0.9999904632568359, "RelationshipType": "DIRECTION", "Id": 27, "BeginOffset": 2421, "EndOffset": 2427, "Text": "inside", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9908167123794556, "RelationshipScore": 0.9996505975723267, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 28, "BeginOffset": 2436, "EndOffset": 2440, "Text": "nose", "Category": "ANATOMY", "Traits": []}]}, {"Id": 28, "BeginOffset": 2436, "EndOffset": 2440, "Score": 0.9908167123794556, "Text": "nose", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 42, "BeginOffset": 2442, "EndOffset": 2453, "Score": 0.9608585238456726, "Text": "weight loss", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8819313049316406}]}, {"Id": 43, "BeginOffset": 2455, "EndOffset": 2465, "Score": 0.8500739336013794, "Text": "itchy skin", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8502691984176636}]}, {"Id": 44, "BeginOffset": 2470, "EndOffset": 2484, "Score": 0.9967330694198608, "Text": "conjunctivitis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.745367169380188}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9589504599571228, "RelationshipScore": 0.6024061441421509, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 29, "BeginOffset": 2461, "EndOffset": 2465, "Text": "skin", "Category": "ANATOMY", "Traits": []}]}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 2598, "EndOffset": 2611}]}, "Section_4": {"Title": "4. possible side effects", "Section_Content": "like all medicines, this medicine can cause side effects, although not everybody gets them. your doctor will discuss these with you and will explain the potential risks and benefits of your treatment. the side effects listed below were seen when dexamethasone was taken for the treatment of multiple myeloma and for the treatment of other diseases. in some cases, the combination of several medicines can increase the side effects of one or the other of these medicines taken separately. neofordex may cause serious mental health problems. these are common (may affect up to 1 in 10 people) and may include: - feeling depressed (including thinking about suicide) - feeling high (mania), very happy (euphoria) or moods that go up and down, - feeling anxious, having difficulty in concentrating and memory loss, - feeling, seeing or hearing things that do not exist or believing in things that are not real, having gloomy thoughts, changing how you act. if you notice any of these symptoms talk to a doctor straight away. other possible side effects may be: very common: may affect more than 1 in 10 people \u2212 increased blood sugar levels (hyperglycaemia); \u2212 constipation; \u2212 having trouble sleeping (insomnia); \u2212 muscle cramps, muscle weakness; \u2212 tiredness, weakness, swelling of the body and face. common: may affect up to 1 in 10 people \u2212 bacterial, viral or fungal infections, including pneumonia, shingles, infections of the nose, mouth, tonsils or throat, bronchitis, herpes, bladder infection, candida infection; \u2212 reduction in the number of red or white blood cells and/or platelets, or increased number of white blood cells, decreased levels of potassium or of albumin (a protein) in the blood, increased levels of uric acid in the blood, changes in liver function tests; \u2212 cushing's syndrome, i.e. weight gain of the trunk and face, excessive sweating, stretch marks, visible swollen capillaries (small blood vessels) and dryness of the skin, growth of extra facial hair (especially in women) and thinning of the hair; \u2212 development of diabetes, loss or increase of appetite, weight gain or weight loss, water retention; \u2212 aggression, confusion, irritability, nervousness, restlessness, altered mood; \u2212 sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet due to nerve damage, dizziness, trembling, headache, loss of or change in the sense of taste; \u2212 cataract, blurred vision; \u2212 fast or irregular heart rhythm, too high or too low blood pressure, formation of blood clots that may clog blood vessels (for example in legs or lungs), swelling of arms or legs, reddening of the skin of the face or body; \u2212 cough, breathing difficulties, difficulties speaking, sore throat or mouth, hoarseness, dry mouth, hiccough, inflammation of the mucous membranes; \u2212 vomiting, nausea, diarrhoea, indigestion, bloating, swollen and/or painful stomach; \u2212 rash, itching, reddened skin, excessive sweating (hyperhidrosis), dry skin, hair loss (alopecia); \u2212 muscle wasting, pain of the muscles, joints, bones or limbs; \u2212 frequent urination; \u2212 pain, fever, chills, fainting, vertigo, exhaustion, drowsiness, impaired sense of balance. uncommon: may affect up to 1 in 100 people \u2212 fever due to a lack of certain white blood cells, lack of all types of blood cells, diminished blood clotting,; 30 \u2212 failure of the thyroid gland to produce normal amounts of hormones (hypothyroidism); \u2212 lack of body water (dehydration) with thirst or headache, decreased magnesium or calcium levels in the blood; \u2212 mood swings, hallucinations; \u2212 stroke, difficulties in coordination or movement, fainting; \u2212 inflammation of the eye and/or eyelids, increased tearing; \u2212 heart attack, abnormally slow heartbeat; \u2212 hives; \u2212 failure of the kidneys. not known: frequency cannot be estimated from the available data \u2212 infection, inflammation of the whole body due to infection (sepsis); \u2212 inability of the body to respond normally to severe stress such as accidents, surgery or illness due to insufficient function of the adrenal glands, severe unusual headache with visual disturbances linked to the withdrawal of treatment, irregularity of menstrual cycles in women, excessive hair growth (hirsutism); \u2212 increased need for diabetes medicine, salt imbalance, potassium loss due to low carbon dioxide levels (a condition called metabolic alkalosis); \u2212 epileptic fits; \u2212 increased pressure in the eye including glaucoma, choroid and retinal disorders (chorioretinopathy); \u2212 inability of the heart to pump enough blood round the body (heart failure); \u2212 ulcers, perforations and/or bleeding in the oesophagus (gullet), stomach or intestine, inflamed pancreas (which may show as pain in the back and abdomen); \u2212 slow wound healing, acne, thinning of the skin, bruising, red or purple discolorations on the skin (purpura); \u2212 thinning of the bones with increased risk of fracture, bone disease, ruptured tendon. reporting of side effects if you get any side effects, talk to your doctor or pharmacist. this includes any possible side effects not listed in this leaflet. you can also report side effects directly via the national reporting system listed in appendix v. by reporting side effects you can help provide more information on the safety of this medicine.", "Entity_Recognition": [{"Text": "neofordex", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Text": "all medicines", "Type": "TREATMENT", "BeginOffset": 5, "EndOffset": 18}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 20, "EndOffset": 33}, {"Id": 15, "BeginOffset": 44, "EndOffset": 56, "Score": 0.9609310626983643, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.6158450841903687}]}, {"Text": "your treatment", "Type": "TREATMENT", "BeginOffset": 185, "EndOffset": 199}, {"Id": 16, "BeginOffset": 205, "EndOffset": 217, "Score": 0.5981289148330688, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5445039868354797}]}, {"Id": 14, "BeginOffset": 246, "EndOffset": 259, "Score": 0.9976149797439575, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 17, "BeginOffset": 291, "EndOffset": 307, "Score": 0.6833735704421997, "Text": "multiple myeloma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9701029062271118}]}, {"Text": "other diseases", "Type": "PROBLEM", "BeginOffset": 333, "EndOffset": 347}, {"Text": "several medicines", "Type": "TREATMENT", "BeginOffset": 383, "EndOffset": 400}, {"Id": 18, "BeginOffset": 418, "EndOffset": 430, "Score": 0.7770512104034424, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.46617594361305237}, {"Name": "DIAGNOSIS", "Score": 0.46843376755714417}]}, {"Text": "these medicines", "Type": "TREATMENT", "BeginOffset": 454, "EndOffset": 469}, {"Text": "serious mental health problems", "Type": "PROBLEM", "BeginOffset": 508, "EndOffset": 538}, {"Id": 20, "BeginOffset": 562, "EndOffset": 568, "Score": 0.23005066812038422, "Text": "affect", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 575, "EndOffset": 576}, {"Text": "10", "Type": "NUMBER", "BeginOffset": 580, "EndOffset": 582}, {"Id": 21, "BeginOffset": 610, "EndOffset": 627, "Score": 0.7021148204803467, "Text": "feeling depressed", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9443706274032593}]}, {"Id": 22, "BeginOffset": 639, "EndOffset": 661, "Score": 0.6023265719413757, "Text": "thinking about suicide", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8834000825881958}]}, {"Text": "feeling high (mania)", "Type": "PROBLEM", "BeginOffset": 665, "EndOffset": 685}, {"Id": 25, "BeginOffset": 687, "EndOffset": 697, "Score": 0.37884125113487244, "Text": "very happy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8675785064697266}]}, {"Id": 26, "BeginOffset": 699, "EndOffset": 707, "Score": 0.7759531140327454, "Text": "euphoria", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8067134022712708}]}, {"Id": 27, "BeginOffset": 712, "EndOffset": 717, "Score": 0.7974168062210083, "Text": "moods", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7485679388046265}]}, {"Id": 28, "BeginOffset": 741, "EndOffset": 756, "Score": 0.3891802430152893, "Text": "feeling anxious", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9698097705841064}]}, {"Text": "difficulty in concentrating and memory loss", "Type": "PROBLEM", "BeginOffset": 765, "EndOffset": 808}, {"Id": 31, "BeginOffset": 812, "EndOffset": 845, "Score": 0.2779500484466553, "Text": "feeling, seeing or hearing things", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7512980699539185}]}, {"Id": 32, "BeginOffset": 913, "EndOffset": 928, "Score": 0.9167718291282654, "Text": "gloomy thoughts", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9393712878227234}, {"Name": "NEGATION", "Score": 0.4860706627368927}]}, {"Text": "these symptoms", "Type": "PROBLEM", "BeginOffset": 973, "EndOffset": 987}, {"Id": 33, "BeginOffset": 1035, "EndOffset": 1047, "Score": 0.9637594819068909, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8376065492630005}]}, {"Id": 34, "BeginOffset": 1073, "EndOffset": 1079, "Score": 0.3058249354362488, "Text": "affect", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 1090, "EndOffset": 1091}, {"Text": "10", "Type": "NUMBER", "BeginOffset": 1095, "EndOffset": 1097}, {"Id": 35, "BeginOffset": 1107, "EndOffset": 1135, "Score": 0.36019444465637207, "Text": "increased blood sugar levels", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7688162326812744}]}, {"Id": 36, "BeginOffset": 1137, "EndOffset": 1151, "Score": 0.9637110233306885, "Text": "hyperglycaemia", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.5718844532966614}]}, {"Id": 37, "BeginOffset": 1156, "EndOffset": 1168, "Score": 0.9984134435653687, "Text": "constipation", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8637270927429199}]}, {"Id": 38, "BeginOffset": 1179, "EndOffset": 1195, "Score": 0.9684290289878845, "Text": "trouble sleeping", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9540270566940308}]}, {"Id": 39, "BeginOffset": 1197, "EndOffset": 1205, "Score": 0.9986131191253662, "Text": "insomnia", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.94261234998703}]}, {"Id": 40, "BeginOffset": 1210, "EndOffset": 1223, "Score": 0.811555027961731, "Text": "muscle cramps", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9684445858001709}]}, {"Id": 41, "BeginOffset": 1225, "EndOffset": 1240, "Score": 0.8877373933792114, "Text": "muscle weakness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9758564233779907}]}, {"Text": "\u2212 tiredness", "Type": "PROBLEM", "BeginOffset": 1242, "EndOffset": 1253}, {"Id": 43, "BeginOffset": 1255, "EndOffset": 1263, "Score": 0.999071478843689, "Text": "weakness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9641475081443787}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9821634292602539, "RelationshipScore": 0.885201632976532, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 3, "BeginOffset": 1290, "EndOffset": 1294, "Text": "face", "Category": "ANATOMY", "Traits": []}]}, {"Text": "swelling of the body and face", "Type": "PROBLEM", "BeginOffset": 1265, "EndOffset": 1294}, {"Id": 45, "BeginOffset": 1308, "EndOffset": 1314, "Score": 0.2545865476131439, "Text": "affect", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 1321, "EndOffset": 1322}, {"Text": "10", "Type": "NUMBER", "BeginOffset": 1326, "EndOffset": 1328}, {"Text": "bacterial, viral or fungal infections", "Type": "PROBLEM", "BeginOffset": 1338, "EndOffset": 1375}, {"Id": 47, "BeginOffset": 1387, "EndOffset": 1396, "Score": 0.9978066086769104, "Text": "pneumonia", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8995081782341003}]}, {"Id": 48, "BeginOffset": 1398, "EndOffset": 1406, "Score": 0.9951069355010986, "Text": "shingles", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.406019926071167}, {"Name": "DIAGNOSIS", "Score": 0.5411516427993774}]}, {"Text": "infections of the nose, mouth, tonsils or throat", "Type": "PROBLEM", "BeginOffset": 1408, "EndOffset": 1456}, {"Id": 50, "BeginOffset": 1458, "EndOffset": 1468, "Score": 0.9842812418937683, "Text": "bronchitis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.43526986241340637}, {"Name": "DIAGNOSIS", "Score": 0.6105255484580994}]}, {"Id": 51, "BeginOffset": 1470, "EndOffset": 1476, "Score": 0.9577709436416626, "Text": "herpes", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.4504937529563904}]}, {"Id": 52, "BeginOffset": 1478, "EndOffset": 1495, "Score": 0.9037311673164368, "Text": "bladder infection", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.40008172392845154}, {"Name": "DIAGNOSIS", "Score": 0.7028242349624634}]}, {"Id": 53, "BeginOffset": 1497, "EndOffset": 1514, "Score": 0.9462668299674988, "Text": "candida infection", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7816441655158997}]}, {"Id": 60, "BeginOffset": 1552, "EndOffset": 1569, "Score": 0.2455202341079712, "Text": "white blood cells", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TEST_NAME", "Traits": []}, {"Id": 61, "BeginOffset": 1577, "EndOffset": 1586, "Score": 0.37795859575271606, "Text": "platelets", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TEST_NAME", "Traits": []}, {"Text": "increased number of white blood cells", "Type": "PROBLEM", "BeginOffset": 1591, "EndOffset": 1628}, {"Text": "decreased levels of potassium", "Type": "PROBLEM", "BeginOffset": 1630, "EndOffset": 1659}, {"Id": 65, "BeginOffset": 1666, "EndOffset": 1673, "Score": 0.819827675819397, "Text": "albumin", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TEST_NAME", "Traits": []}, {"Text": "a protein", "Type": "TEST", "BeginOffset": 1675, "EndOffset": 1684}, {"Text": "the blood", "Type": "TEST", "BeginOffset": 1689, "EndOffset": 1698}, {"Text": "increased levels of uric acid in the blood", "Type": "PROBLEM", "BeginOffset": 1700, "EndOffset": 1742}, {"Id": 70, "BeginOffset": 1755, "EndOffset": 1775, "Score": 0.9071754813194275, "Text": "liver function tests", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TEST_NAME", "Traits": []}, {"Id": 54, "BeginOffset": 1779, "EndOffset": 1797, "Score": 0.825695276260376, "Text": "cushing's syndrome", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8514207601547241}]}, {"Text": "weight gain of the trunk and face", "Type": "PROBLEM", "BeginOffset": 1804, "EndOffset": 1837}, {"Text": "excessive sweating", "Type": "PROBLEM", "BeginOffset": 1839, "EndOffset": 1857}, {"Id": 57, "BeginOffset": 1859, "EndOffset": 1872, "Score": 0.6730884909629822, "Text": "stretch marks", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7972132563591003}]}, {"Text": "visible swollen capillaries", "Type": "PROBLEM", "BeginOffset": 1874, "EndOffset": 1901}, {"Text": "small blood vessels)", "Type": "PROBLEM", "BeginOffset": 1903, "EndOffset": 1923}, {"Text": "dryness of the skin", "Type": "PROBLEM", "BeginOffset": 1928, "EndOffset": 1947}, {"Text": "extra facial hair", "Type": "PROBLEM", "BeginOffset": 1959, "EndOffset": 1976}, {"Id": 105, "BeginOffset": 2003, "EndOffset": 2023, "Score": 0.45587021112442017, "Text": "thinning of the hair", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.6255655288696289}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9880841374397278, "RelationshipScore": 0.9473121166229248, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 71, "BeginOffset": 1943, "EndOffset": 1947, "Text": "skin", "Category": "ANATOMY", "Traits": []}]}, {"Id": 106, "BeginOffset": 2042, "EndOffset": 2050, "Score": 0.9904126524925232, "Text": "diabetes", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 107, "BeginOffset": 2052, "EndOffset": 2080, "Score": 0.526874840259552, "Text": "loss or increase of appetite", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9586963057518005}]}, {"Id": 108, "BeginOffset": 2082, "EndOffset": 2093, "Score": 0.9964843988418579, "Text": "weight gain", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9302616119384766}]}, {"Id": 109, "BeginOffset": 2097, "EndOffset": 2108, "Score": 0.9971554279327393, "Text": "weight loss", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9383026957511902}]}, {"Id": 110, "BeginOffset": 2110, "EndOffset": 2125, "Score": 0.9815292358398438, "Text": "water retention", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.957923173904419}]}, {"Id": 111, "BeginOffset": 2129, "EndOffset": 2139, "Score": 0.8764538168907166, "Text": "aggression", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7507184743881226}]}, {"Id": 112, "BeginOffset": 2141, "EndOffset": 2150, "Score": 0.9987242817878723, "Text": "confusion", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9599183201789856}]}, {"Id": 113, "BeginOffset": 2152, "EndOffset": 2164, "Score": 0.9993630051612854, "Text": "irritability", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9560819864273071}]}, {"Id": 114, "BeginOffset": 2166, "EndOffset": 2177, "Score": 0.9985160231590271, "Text": "nervousness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9714953899383545}]}, {"Id": 115, "BeginOffset": 2179, "EndOffset": 2191, "Score": 0.9952567219734192, "Text": "restlessness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9673359990119934}]}, {"Id": 116, "BeginOffset": 2193, "EndOffset": 2205, "Score": 0.9902858138084412, "Text": "altered mood", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9282354116439819}]}, {"Text": "\u2212 sensitivity", "Type": "PROBLEM", "BeginOffset": 2207, "EndOffset": 2220}, {"Id": 118, "BeginOffset": 2222, "EndOffset": 2230, "Score": 0.9990583062171936, "Text": "numbness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9765670299530029}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9992350339889526, "RelationshipScore": 0.6705983281135559, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 74, "BeginOffset": 2269, "EndOffset": 2273, "Text": "skin", "Category": "ANATOMY", "Traits": []}]}, {"Id": 119, "BeginOffset": 2232, "EndOffset": 2240, "Score": 0.9876125454902649, "Text": "tingling", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9531388282775879}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9992350339889526, "RelationshipScore": 0.9868152141571045, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 74, "BeginOffset": 2269, "EndOffset": 2273, "Text": "skin", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9932698607444763, "RelationshipScore": 0.600183367729187, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 76, "BeginOffset": 2299, "EndOffset": 2303, "Text": "feet", "Category": "ANATOMY", "Traits": []}]}, {"Text": "burning sensation of the skin", "Type": "PROBLEM", "BeginOffset": 2244, "EndOffset": 2273}, {"Text": "pain in the hands or feet", "Type": "PROBLEM", "BeginOffset": 2278, "EndOffset": 2303}, {"Id": 122, "BeginOffset": 2311, "EndOffset": 2323, "Score": 0.6441371440887451, "Text": "nerve damage", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9208914041519165}]}, {"Id": 123, "BeginOffset": 2325, "EndOffset": 2334, "Score": 0.9994877576828003, "Text": "dizziness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9756549596786499}]}, {"Id": 124, "BeginOffset": 2336, "EndOffset": 2345, "Score": 0.9988382458686829, "Text": "trembling", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9812330007553101}]}, {"Id": 125, "BeginOffset": 2347, "EndOffset": 2355, "Score": 0.9995287656784058, "Text": "headache", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9817386269569397}]}, {"Id": 126, "BeginOffset": 2357, "EndOffset": 2396, "Score": 0.9575966596603394, "Text": "loss of or change in the sense of taste", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9324267506599426}]}, {"Id": 127, "BeginOffset": 2400, "EndOffset": 2408, "Score": 0.9577040076255798, "Text": "cataract", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7003832459449768}]}, {"Id": 128, "BeginOffset": 2410, "EndOffset": 2424, "Score": 0.9089799523353577, "Text": "blurred vision", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9528721570968628}]}, {"Text": "\u2212 fast or irregular heart rhythm", "Type": "PROBLEM", "BeginOffset": 2426, "EndOffset": 2458}, {"Text": "too high or too low blood pressure", "Type": "PROBLEM", "BeginOffset": 2460, "EndOffset": 2494}, {"Id": 131, "BeginOffset": 2509, "EndOffset": 2520, "Score": 0.9535943269729614, "Text": "blood clots", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.891622006893158}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.3166052997112274, "RelationshipScore": 0.9995427131652832, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 79, "BeginOffset": 2535, "EndOffset": 2548, "Text": "blood vessels", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.990452766418457, "RelationshipScore": 0.9966585636138916, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 80, "BeginOffset": 2565, "EndOffset": 2569, "Text": "legs", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9943776726722717, "RelationshipScore": 0.9938001036643982, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 81, "BeginOffset": 2573, "EndOffset": 2578, "Text": "lungs", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.998120129108429, "RelationshipScore": 0.6342987418174744, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 82, "BeginOffset": 2593, "EndOffset": 2597, "Text": "arms", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9979721903800964, "RelationshipScore": 0.7536217570304871, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 83, "BeginOffset": 2601, "EndOffset": 2605, "Text": "legs", "Category": "ANATOMY", "Traits": []}]}, {"Id": 79, "BeginOffset": 2535, "EndOffset": 2548, "Score": 0.3166052997112274, "Text": "blood vessels", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 80, "BeginOffset": 2565, "EndOffset": 2569, "Score": 0.990452766418457, "Text": "legs", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 81, "BeginOffset": 2573, "EndOffset": 2578, "Score": 0.9943776726722717, "Text": "lungs", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "swelling of arms or legs", "Type": "PROBLEM", "BeginOffset": 2581, "EndOffset": 2605}, {"Id": 133, "BeginOffset": 2607, "EndOffset": 2648, "Score": 0.3799442946910858, "Text": "reddening of the skin of the face or body", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8151572346687317}]}, {"Id": 134, "BeginOffset": 2652, "EndOffset": 2657, "Score": 0.9876441359519958, "Text": "cough", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9664453268051147}]}, {"Id": 135, "BeginOffset": 2659, "EndOffset": 2681, "Score": 0.9853804707527161, "Text": "breathing difficulties", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9595316052436829}]}, {"Id": 136, "BeginOffset": 2683, "EndOffset": 2704, "Score": 0.9732435345649719, "Text": "difficulties speaking", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9483603835105896}]}, {"Id": 137, "BeginOffset": 2706, "EndOffset": 2717, "Score": 0.7022244334220886, "Text": "sore throat", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8787317872047424}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9821212291717529, "RelationshipScore": 0.4754446744918823, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 88, "BeginOffset": 2721, "EndOffset": 2726, "Text": "mouth", "Category": "ANATOMY", "Traits": []}, {"Type": "SYSTEM_ORGAN_SITE", "Score": 0.998815655708313, "RelationshipScore": 0.6262189149856567, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 90, "BeginOffset": 2781, "EndOffset": 2797, "Text": "mucous membranes", "Category": "ANATOMY", "Traits": []}]}, {"Id": 138, "BeginOffset": 2721, "EndOffset": 2726, "Score": 0.39610573649406433, "Text": "mouth", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.6819822192192078}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9967291355133057, "RelationshipScore": 0.48146024346351624, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 87, "BeginOffset": 2711, "EndOffset": 2717, "Text": "throat", "Category": "ANATOMY", "Traits": []}]}, {"Id": 139, "BeginOffset": 2728, "EndOffset": 2738, "Score": 0.998301088809967, "Text": "hoarseness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9735983610153198}]}, {"Id": 140, "BeginOffset": 2740, "EndOffset": 2749, "Score": 0.533933699131012, "Text": "dry mouth", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.969616174697876}]}, {"Id": 141, "BeginOffset": 2751, "EndOffset": 2759, "Score": 0.997102677822113, "Text": "hiccough", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9764328598976135}]}, {"Text": "inflammation of the mucous membranes", "Type": "PROBLEM", "BeginOffset": 2761, "EndOffset": 2797}, {"Id": 143, "BeginOffset": 2801, "EndOffset": 2809, "Score": 0.9952340722084045, "Text": "vomiting", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.972601056098938}]}, {"Id": 144, "BeginOffset": 2811, "EndOffset": 2817, "Score": 0.9996862411499023, "Text": "nausea", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9814873933792114}]}, {"Id": 145, "BeginOffset": 2819, "EndOffset": 2828, "Score": 0.9994751811027527, "Text": "diarrhoea", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9794146418571472}]}, {"Id": 146, "BeginOffset": 2830, "EndOffset": 2841, "Score": 0.999384880065918, "Text": "indigestion", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9875370860099792}]}, {"Id": 147, "BeginOffset": 2843, "EndOffset": 2851, "Score": 0.9990092515945435, "Text": "bloating", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9857211112976074}]}, {"Text": "swollen and/or painful stomach", "Type": "PROBLEM", "BeginOffset": 2853, "EndOffset": 2883}, {"Text": "\u2212 rash", "Type": "PROBLEM", "BeginOffset": 2885, "EndOffset": 2891}, {"Id": 151, "BeginOffset": 2893, "EndOffset": 2900, "Score": 0.9988538026809692, "Text": "itching", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.980863094329834}]}, {"Id": 152, "BeginOffset": 2902, "EndOffset": 2915, "Score": 0.8309541940689087, "Text": "reddened skin", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9406369924545288}]}, {"Text": "excessive sweating (hyperhidrosis)", "Type": "PROBLEM", "BeginOffset": 2917, "EndOffset": 2951}, {"Id": 155, "BeginOffset": 2953, "EndOffset": 2961, "Score": 0.9247440695762634, "Text": "dry skin", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9274178743362427}]}, {"Text": "hair loss (alopecia)", "Type": "PROBLEM", "BeginOffset": 2963, "EndOffset": 2983}, {"Text": "\u2212 muscle wasting", "Type": "PROBLEM", "BeginOffset": 2985, "EndOffset": 3001}, {"Text": "pain of the muscles, joints, bones or limbs", "Type": "PROBLEM", "BeginOffset": 3003, "EndOffset": 3046}, {"Text": "\u2212 frequent urination", "Type": "PROBLEM", "BeginOffset": 3048, "EndOffset": 3068}, {"Text": "\u2212 pain", "Type": "PROBLEM", "BeginOffset": 3070, "EndOffset": 3076}, {"Id": 162, "BeginOffset": 3078, "EndOffset": 3083, "Score": 0.9992414712905884, "Text": "fever", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9833899140357971}]}, {"Id": 163, "BeginOffset": 3085, "EndOffset": 3091, "Score": 0.9998307228088379, "Text": "chills", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9935759902000427}]}, {"Id": 164, "BeginOffset": 3093, "EndOffset": 3101, "Score": 0.9987776875495911, "Text": "fainting", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9844276309013367}]}, {"Id": 165, "BeginOffset": 3103, "EndOffset": 3110, "Score": 0.9994146823883057, "Text": "vertigo", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9874842762947083}]}, {"Id": 166, "BeginOffset": 3112, "EndOffset": 3122, "Score": 0.9843544960021973, "Text": "exhaustion", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9660354256629944}]}, {"Id": 167, "BeginOffset": 3124, "EndOffset": 3134, "Score": 0.998746395111084, "Text": "drowsiness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9840894937515259}]}, {"Id": 168, "BeginOffset": 3136, "EndOffset": 3161, "Score": 0.9528899192810059, "Text": "impaired sense of balance", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9253641366958618}]}, {"Id": 169, "BeginOffset": 3177, "EndOffset": 3183, "Score": 0.21991688013076782, "Text": "affect", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 3190, "EndOffset": 3191}, {"Text": "100", "Type": "NUMBER", "BeginOffset": 3195, "EndOffset": 3198}, {"Id": 170, "BeginOffset": 3208, "EndOffset": 3213, "Score": 0.9731228351593018, "Text": "fever", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8532910346984863}]}, {"Text": "a lack of certain white blood cells", "Type": "PROBLEM", "BeginOffset": 3221, "EndOffset": 3256}, {"Text": "blood cells", "Type": "PROBLEM", "BeginOffset": 3279, "EndOffset": 3290}, {"Text": "diminished blood clotting", "Type": "PROBLEM", "BeginOffset": 3292, "EndOffset": 3317}, {"Id": 172, "BeginOffset": 3325, "EndOffset": 3391, "Score": 0.3627064824104309, "Text": "failure of the thyroid gland to produce normal amounts of hormones", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 173, "BeginOffset": 3393, "EndOffset": 3407, "Score": 0.9853455424308777, "Text": "hypothyroidism", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7500500082969666}]}, {"Text": "body water (dehydration)", "Type": "PROBLEM", "BeginOffset": 3420, "EndOffset": 3444}, {"Id": 176, "BeginOffset": 3450, "EndOffset": 3456, "Score": 0.9208530783653259, "Text": "thirst", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.889135479927063}]}, {"Id": 177, "BeginOffset": 3460, "EndOffset": 3468, "Score": 0.9977549910545349, "Text": "headache", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9527255892753601}]}, {"Id": 178, "BeginOffset": 3470, "EndOffset": 3520, "Score": 0.7629074454307556, "Text": "decreased magnesium or calcium levels in the blood", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7718803882598877}]}, {"Id": 179, "BeginOffset": 3524, "EndOffset": 3535, "Score": 0.953924298286438, "Text": "mood swings", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9694275856018066}]}, {"Id": 180, "BeginOffset": 3537, "EndOffset": 3551, "Score": 0.9970569610595703, "Text": "hallucinations", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9757594466209412}]}, {"Id": 181, "BeginOffset": 3555, "EndOffset": 3561, "Score": 0.9948126077651978, "Text": "stroke", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8539917469024658}]}, {"Id": 182, "BeginOffset": 3563, "EndOffset": 3603, "Score": 0.9550049901008606, "Text": "difficulties in coordination or movement", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9419580101966858}]}, {"Id": 183, "BeginOffset": 3605, "EndOffset": 3613, "Score": 0.9750115275382996, "Text": "fainting", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.9504297375679016}]}, {"Text": "\u2212 inflammation of the eye and/or eyelids", "Type": "PROBLEM", "BeginOffset": 3615, "EndOffset": 3655}, {"Text": "increased tearing", "Type": "PROBLEM", "BeginOffset": 3657, "EndOffset": 3674}, {"Text": "\u2212 heart attack", "Type": "PROBLEM", "BeginOffset": 3676, "EndOffset": 3690}, {"Id": 187, "BeginOffset": 3692, "EndOffset": 3717, "Score": 0.72092205286026, "Text": "abnormally slow heartbeat", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8714357614517212}]}, {"Id": 188, "BeginOffset": 3721, "EndOffset": 3726, "Score": 0.9491174817085266, "Text": "hives", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5943277478218079}]}, {"Text": "\u2212 failure of the kidneys", "Type": "PROBLEM", "BeginOffset": 3728, "EndOffset": 3752}, {"Id": 190, "BeginOffset": 3765, "EndOffset": 3774, "Score": 0.37324240803718567, "Text": "frequency", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 211, "BeginOffset": 3821, "EndOffset": 3830, "Score": 0.9581640958786011, "Text": "infection", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6609136462211609}]}, {"Text": "inflammation of the whole body", "Type": "PROBLEM", "BeginOffset": 3832, "EndOffset": 3862}, {"Id": 213, "BeginOffset": 3870, "EndOffset": 3879, "Score": 0.9528131484985352, "Text": "infection", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7700435519218445}]}, {"Id": 214, "BeginOffset": 3881, "EndOffset": 3887, "Score": 0.9881659746170044, "Text": "sepsis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8985418677330017}]}, {"Id": 215, "BeginOffset": 3892, "EndOffset": 3933, "Score": 0.5272806286811829, "Text": "inability of the body to respond normally", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 192, "BeginOffset": 3909, "EndOffset": 3913, "Score": 0.8355972170829773, "Text": "body", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "severe stress", "Type": "PROBLEM", "BeginOffset": 3937, "EndOffset": 3950}, {"Id": 217, "BeginOffset": 3959, "EndOffset": 3968, "Score": 0.4182188808917999, "Text": "accidents", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 259, "BeginOffset": 3970, "EndOffset": 3977, "Score": 0.5284119248390198, "Text": "surgery", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "PROCEDURE_NAME", "Traits": []}, {"Id": 218, "BeginOffset": 3981, "EndOffset": 3988, "Score": 0.3992382287979126, "Text": "illness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Text": "insufficient function of the adrenal glands", "Type": "PROBLEM", "BeginOffset": 3996, "EndOffset": 4039}, {"Text": "severe unusual headache", "Type": "PROBLEM", "BeginOffset": 4041, "EndOffset": 4064}, {"Id": 220, "BeginOffset": 4070, "EndOffset": 4089, "Score": 0.9124631881713867, "Text": "visual disturbances", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.6960282921791077}]}, {"Text": "treatment", "Type": "TREATMENT", "BeginOffset": 4118, "EndOffset": 4127}, {"Text": "irregularity of menstrual cycles in women", "Type": "PROBLEM", "BeginOffset": 4129, "EndOffset": 4170}, {"Text": "excessive hair growth (hirsutism)", "Type": "PROBLEM", "BeginOffset": 4172, "EndOffset": 4205}, {"Id": 260, "BeginOffset": 4228, "EndOffset": 4245, "Score": 0.3548913896083832, "Text": "diabetes medicine", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "salt imbalance", "Type": "PROBLEM", "BeginOffset": 4247, "EndOffset": 4261}, {"Id": 227, "BeginOffset": 4263, "EndOffset": 4277, "Score": 0.8830428719520569, "Text": "potassium loss", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.42081138491630554}, {"Name": "DIAGNOSIS", "Score": 0.4346477687358856}]}, {"Text": "low carbon dioxide levels", "Type": "PROBLEM", "BeginOffset": 4285, "EndOffset": 4310}, {"Id": 228, "BeginOffset": 4331, "EndOffset": 4350, "Score": 0.7820268869400024, "Text": "metabolic alkalosis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8929369449615479}]}, {"Text": "\u2212 epileptic fits", "Type": "PROBLEM", "BeginOffset": 4353, "EndOffset": 4369}, {"Text": "\u2212 increased pressure in the eye", "Type": "PROBLEM", "BeginOffset": 4371, "EndOffset": 4402}, {"Id": 231, "BeginOffset": 4413, "EndOffset": 4421, "Score": 0.9906319379806519, "Text": "glaucoma", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.949668824672699}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9821286201477051, "RelationshipScore": 0.923240065574646, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 195, "BeginOffset": 4399, "EndOffset": 4402, "Text": "eye", "Category": "ANATOMY", "Traits": []}]}, {"Text": "choroid and retinal disorders", "Type": "PROBLEM", "BeginOffset": 4423, "EndOffset": 4452}, {"Id": 234, "BeginOffset": 4454, "EndOffset": 4471, "Score": 0.9494131207466125, "Text": "chorioretinopathy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8920223712921143}]}, {"Id": 235, "BeginOffset": 4476, "EndOffset": 4534, "Score": 0.6524009704589844, "Text": "inability of the heart to pump enough blood round the body", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 196, "BeginOffset": 4493, "EndOffset": 4498, "Score": 0.9888379573822021, "Text": "heart", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 236, "BeginOffset": 4536, "EndOffset": 4549, "Score": 0.9403313994407654, "Text": "heart failure", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9584877490997314}]}, {"Text": "\u2212 ulcers", "Type": "PROBLEM", "BeginOffset": 4552, "EndOffset": 4560}, {"Id": 238, "BeginOffset": 4562, "EndOffset": 4574, "Score": 0.7089805006980896, "Text": "perforations", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.43506333231925964}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.8979458212852478, "RelationshipScore": 0.9362443685531616, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 199, "BeginOffset": 4598, "EndOffset": 4608, "Text": "oesophagus", "Category": "ANATOMY", "Traits": []}]}, {"Text": "bleeding in the oesophagus (gullet), stomach or intestine, inflamed pancreas", "Type": "PROBLEM", "BeginOffset": 4582, "EndOffset": 4658}, {"Text": "pain in the back and abdomen", "Type": "PROBLEM", "BeginOffset": 4678, "EndOffset": 4706}, {"Text": "slow wound healing", "Type": "PROBLEM", "BeginOffset": 4711, "EndOffset": 4729}, {"Id": 243, "BeginOffset": 4731, "EndOffset": 4735, "Score": 0.9979153275489807, "Text": "acne", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.5235008597373962}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9980807304382324, "RelationshipScore": 0.8664654493331909, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 205, "BeginOffset": 4753, "EndOffset": 4757, "Text": "skin", "Category": "ANATOMY", "Traits": []}]}, {"Text": "thinning of the skin", "Type": "PROBLEM", "BeginOffset": 4737, "EndOffset": 4757}, {"Id": 245, "BeginOffset": 4759, "EndOffset": 4767, "Score": 0.989267885684967, "Text": "bruising", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SIGN", "Score": 0.4647308588027954}, {"Name": "SYMPTOM", "Score": 0.6691511869430542}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9980807304382324, "RelationshipScore": 0.9067290425300598, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 205, "BeginOffset": 4753, "EndOffset": 4757, "Text": "skin", "Category": "ANATOMY", "Traits": []}]}, {"Text": "red or purple discolorations on the skin (purpura", "Type": "PROBLEM", "BeginOffset": 4769, "EndOffset": 4818}, {"Text": "\u2212 thinning of the bones", "Type": "PROBLEM", "BeginOffset": 4821, "EndOffset": 4844}, {"Id": 250, "BeginOffset": 4868, "EndOffset": 4876, "Score": 0.9897947907447815, "Text": "fracture", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9347114562988281}]}, {"Id": 251, "BeginOffset": 4878, "EndOffset": 4890, "Score": 0.9589991569519043, "Text": "bone disease", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9069014191627502}]}, {"Id": 252, "BeginOffset": 4892, "EndOffset": 4907, "Score": 0.9181709289550781, "Text": "ruptured tendon", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6855838894844055}]}, {"Id": 253, "BeginOffset": 4922, "EndOffset": 4934, "Score": 0.9316697120666504, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5002785325050354}, {"Name": "DIAGNOSIS", "Score": 0.4607936143875122}]}, {"Id": 254, "BeginOffset": 4950, "EndOffset": 4962, "Score": 0.9065960645675659, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.6337698698043823}]}, {"Id": 255, "BeginOffset": 5026, "EndOffset": 5038, "Score": 0.9518405795097351, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5456344485282898}, {"Name": "DIAGNOSIS", "Score": 0.45343947410583496}]}, {"Id": 256, "BeginOffset": 5087, "EndOffset": 5099, "Score": 0.8507976531982422, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.633181631565094}]}, {"Id": 257, "BeginOffset": 5153, "EndOffset": 5164, "Score": 0.37304866313934326, "Text": "appendix v.", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5280402302742004}, {"Name": "DIAGNOSIS", "Score": 0.42126646637916565}]}, {"Id": 258, "BeginOffset": 5178, "EndOffset": 5190, "Score": 0.8578768372535706, "Text": "side effects", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.6894659399986267}]}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 5246, "EndOffset": 5259}]}, "Section_5": {"Title": "5. how to store neofordex", "Section_Content": "keep this medicine out of the sight and reach of children. do not use this medicine after the expiry date which is stated on the carton and blister after exp. the expiry date refers to the last day of that month. do not use this medicine if you notice any defects, or any signs of deterioration of the tablets or packaging. this medicine does not require any special temperature storage conditions. keep tablets in the blister packaging until you take them. if you are using a pill organiser box, use the perforation to separate individual tablets from the blister without opening the packaging. throw away half tablets that you have not taken. do not throw away any medicines via wastewater or household waste. ask your pharmacist how to throw away medicines you no longer use. these measures will help protect the environment.", "Entity_Recognition": [{"Text": "neofordex", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 70, "EndOffset": 83}, {"Text": "this medicine", "Type": "TREATMENT", "BeginOffset": 224, "EndOffset": 237}, {"Text": "any defects", "Type": "PROBLEM", "BeginOffset": 252, "EndOffset": 263}, {"Text": "deterioration of the tablets", "Type": "PROBLEM", "BeginOffset": 281, "EndOffset": 309}, {"Text": "packaging", "Type": "TREATMENT", "BeginOffset": 313, "EndOffset": 322}, {"Text": "tablets", "Type": "TREATMENT", "BeginOffset": 404, "EndOffset": 411}, {"Text": "the blister packaging", "Type": "TREATMENT", "BeginOffset": 415, "EndOffset": 436}, {"Text": "a pill organiser box", "Type": "TREATMENT", "BeginOffset": 475, "EndOffset": 495}, {"Text": "the perforation", "Type": "PROBLEM", "BeginOffset": 501, "EndOffset": 516}, {"Text": "the blister", "Type": "PROBLEM", "BeginOffset": 553, "EndOffset": 564}, {"Text": "the packaging", "Type": "TREATMENT", "BeginOffset": 581, "EndOffset": 594}]}, "Section_6": {"Title": "6. contents of the pack and other information", "Section_Content": "what neofordex contains - the active substance is dexamethasone. each tablet contains dexamethasone acetate equivalent to 40 mg dexamethasone. - the other ingredients are lactose monohydrate, microcrystalline cellulose, magnesium stearate and colloidal anhydrous silica (see section 2). what neofordex looks like and contents of the pack each tablet is white, oblong in shape, with a score line on one face. the tablet can be divided into two equal halves. each carton contains 10 x 1 tablets in opa/aluminium /pvc-aluminium perforated unit dose blister.", "Entity_Recognition": [{"Text": "neofordex", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Id": 1, "BeginOffset": 50, "EndOffset": 63, "Score": 0.9992916584014893, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "FORM", "Score": 0.8398175239562988, "RelationshipScore": 0.9998785257339478, "RelationshipType": "FORM", "Id": 2, "BeginOffset": 70, "EndOffset": 76, "Text": "tablet", "Category": "MEDICATION", "Traits": []}]}, {"Id": 3, "BeginOffset": 86, "EndOffset": 107, "Score": 0.8187251687049866, "Text": "dexamethasone acetate", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "FORM", "Score": 0.8398175239562988, "RelationshipScore": 0.7837391495704651, "RelationshipType": "FORM", "Id": 2, "BeginOffset": 70, "EndOffset": 76, "Text": "tablet", "Category": "MEDICATION", "Traits": []}]}, {"Text": "40", "Type": "NUMBER", "BeginOffset": 122, "EndOffset": 124}, {"Id": 5, "BeginOffset": 128, "EndOffset": 141, "Score": 0.9997486472129822, "Text": "dexamethasone", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "DOSAGE", "Score": 0.9869434833526611, "RelationshipScore": 0.9999850988388062, "RelationshipType": "DOSAGE", "Id": 4, "BeginOffset": 122, "EndOffset": 127, "Text": "40 mg", "Category": "MEDICATION", "Traits": []}]}, {"Id": 6, "BeginOffset": 171, "EndOffset": 190, "Score": 0.6390437483787537, "Text": "lactose monohydrate", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 7, "BeginOffset": 192, "EndOffset": 218, "Score": 0.9953265190124512, "Text": "microcrystalline cellulose", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 8, "BeginOffset": 220, "EndOffset": 238, "Score": 0.9936284422874451, "Text": "magnesium stearate", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 9, "BeginOffset": 243, "EndOffset": 269, "Score": 0.9665902853012085, "Text": "colloidal anhydrous silica", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 0, "BeginOffset": 402, "EndOffset": 406, "Score": 0.777242124080658, "Text": "face", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "the tablet", "Type": "TREATMENT", "BeginOffset": 408, "EndOffset": 418}, {"Text": "10", "Type": "NUMBER", "BeginOffset": 478, "EndOffset": 480}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 483, "EndOffset": 484}, {"Text": "opa/aluminium /pvc", "Type": "TREATMENT", "BeginOffset": 496, "EndOffset": 514}, {"Text": "aluminium perforated unit dose blister", "Type": "TREATMENT", "BeginOffset": 515, "EndOffset": 553}]}}